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Epilepsy is one of the most common diseases that affect both dogs and humans and may be 
potentially threatening when not treated. The cause of idiopathic epilepsy remains unclear, but 
many factors have been identified as potential triggers for developing epilepsy. Nowadays many 
drugs are available for the treatment of epilepsy, but the cases of total remission are rare and 
there is no cure. Moreover, most of anti-epileptic drugs (AEDs) induce side effects. 
This dissertation includes a literature review outlining the topic of idiopathic epilepsy, together 
with a preliminary, exploratory study with the objective of investigating possible alterations on 
blood parameters that might be induced by repeated seizures. Neuroinflammation may be a 
consequence of seizures, which possibly induces alterations on blood parameters.  
The results suggest that a status of inflammation is likely following seizures, however, further 
studies regarding the topic are necessary to achieve more clear and precise information.  
 










O IMPACTO DA EPILEPSIA IDIOPÁTICA CANINA NOS PARÂMETROS 
DE HEMOGRAMA  
 
Epilepsia é uma síndrome neurológica frequente em cães e humanos e que pode ser 
potencialmente fatal caso não seja devidamente tratada. A causa da epilepsia idiopática 
permanece desconhecida, porém vários fatores têm sido apontados como desencadeantes desta 
síndrome. Atualmente, várias drogas estão disponíveis para o tratamento da epilepsia, mas são 
raros os casos de total remissão e não existe cura. Além disso, estas drogas possuem vários 
efeitos secundários associados. 
A presente dissertação incluí uma revisão bibliográfica sobre a epilepsia idiopática em conjunto 
com um estudo preliminar e exploratório cujo principal objetivo foi investigar possíveis alterações 
nos parâmetros de hemograma que poderiam ser induzidos por convulsões recorrentes. A 
neuroinflamação pode ser um resultado de convulsões recorrentes e um estado inflamatório pode 
levar a alterações nos parâmetros de hemograma. 
Os resultados sugerem que a inflamação é provavelmente desencadeada após episódios 
convulsivos, porém, mais estudos relacionados com este tópico são necessários. 
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This dissertation was written following a five-month externship at Hospital Veterinário Breed 
Paredes, from 5th November 2018 to 5th April 2019 and under the guidance of a supervisor chosen 
by the trainee and hospital staff. 
This externship offered the opportunity to be in contact with different areas of veterinary medicine 
that included orthopedics and soft tissue surgery, diagnostics, internal medicine including specific 
areas such as dermatology, nutrition, oncology, ophthalmology, cardiology, dentistry, emergency 
and critical care medicine.  
Throughout this externship the trainee developed essential skills that would be important for the 
exercise of her future profession. Also, the required data for this study was collected there and 
subsequently organized and analyzed, resulting in the dissertation below.




1. LITERATURE REVIEW 
  
 INTRODUCTION 
Epilepsy is a neurological syndrome and known to be one of the most common among the canine 
and feline population 1, as well as in humans 2. An epileptic seizure can be defined as abrupt, 
involuntary electrical discharges happening within a population of neurons, leading to sudden and 
involuntary muscle movements and behaviour changes 3–5. As said by Moore, epileptic seizures 
are a clinical manifestation of abnormal hyper-synchronisation of neurons within the forebrain 6. 
The effect of multiple and continued anomalous discharges will affect the edge neurons and these 
discharges will further progress to other neurons 7. As stated by Berendt, an epileptic seizure is 
characterised for consciousness impairment in most of the cases, paroxysmal events and 
identical clinical manifestations in all episodes 8. The formation of these hypersynchronous 
discharges is called epileptogenesis 7. According to De Risio et al., inflammation, infection, 
metabolic disorders, trauma, tumours and oxygen deprivation can lead to abnormal neuronal 
activity 9. Regardless of the mechanism, the epileptic seizure is defined as a brain disorder 8. 
Given the ideal conditions, an animal may experience a seizure and many factors may be involved 
in its progression 4.  
The term epilepsy is only considered when two or more seizures occur within more than 24 hours 
between each event 1,10. Therefore, it is crucial to explore underlying causes that may lead to 
seizures, being an imminent emergency if the epileptic episode is prolonged in time 10. A single 
seizure may be a result of cerebral overload after brain injury due to multiple causes and, even 
though epilepsy should be considered as a differential diagnosis, it is unlikely to be diagnosed 
when direct damage is inflicted to the brain 8. Regarding epilepsy, the term idiopathic refers to the 
epilepsy of unknown cause when in the presence of unprovoked seizures and absence of brain 
abnormalities, thus with a possible hereditary predisposition 4,11,12. Idiopathic epilepsy (IE) is 
known to be the most common type of epilepsy in dogs 13–16. 
The presence of seizures is not pathognomonic for IE. When undertaking diagnosis, it is essential 
to keep in mind that many different disorders may induce seizures 17. Nevertheless, there may be 
cases where the aetiological cause is unknown, being IE the most likely diagnosis 9. Usually, 
these abnormal electrical signals can be propagated throughout different structures in the brain 
and depending upon the structure that has been affected, the clinical manifestations may be 
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According to Heske et al., the estimated prevalence of epilepsy within the canine population is 
0.75% 18. In humans, the prevalence of epilepsy is around 1% 19. In other studies, a prevalence 
of 0.62% - 0.75% of epilepsy in dogs was also reported 20,21. The prevalence of epilepsy within a 
specific group of dogs included in a study in Japan was 1.9%, having a prevalence of 0.9% of IE 
compared with the 0.4% of structural epilepsy (StE) 22.  
Male dogs seemed more likely to develop epilepsy compared with female dogs 15,23,24. When 
considering dogs diagnosed with IE, males have a shorter life span when compared with females 
25.  
As described in many studies, some breeds may have a higher likelihood for IE, including the 
Labrador Retriever 18,23,26, Boxer 18,27, Belgian Shepherds 18,28,29, German Shepherds 23, Border 
Collies 23,30, Chihuahua 15, Bernese Mountain Dogs 24, Lagotto Romagnolo 31 and Toy Poodles  
15. Pure breeds have a higher incidence of IE compared with cross-breeds 32.  
Breeds which have a higher incidence rate of IE can be genetically predisposed to this disease 
18. IE is likely to be diagnosed in dogs whose seizure onset occurred between six months to six 
years 33, with a clinical history of repeated seizures and normal consciousness after episodes 
23,34,35. According to Smith et al., a 97% confidence diagnosis of IE was found in such 
presentations 34. As stated by Coates and O’Brien, only one-third of the dogs aged between one 
to five years are diagnosed with StE 36. It is possible that some of these dogs that experienced 
seizures may not have a definitive cause for their seizures 16,37. It is unlikely that structural brain 
alterations are detected during magnetic resonance imaging (MRI) in epileptic dogs younger than 
six years 34. However, it is likely to find such alterations in epileptic dogs older than six years 34.  
Many studies found a higher prevalence of IE in many purebred and this strongly suggests a 
genetic predisposition 4,30. In fact, in human medicine, it is said that 40% of epileptic patients have 
a genetic disorder underlying their epilepsy 38. Only one type of epilepsy, related to a genetic 
disorder  was described in Lagotto Romagnolo dogs and it is associated with a mutation in the 
LGI2 gene 31. This mutation leads to a defect on the regular conformation of proteins that 
constitute the neuronal membrane, therefore it is recognised as a channelopathy 3,12,31. This 
finding emphasises the correlation between IE and genetic predisposition 30. 
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1.2.1 PRECIPITATING FACTORS 
 
Many precipitating factors for seizures are known from human medicine and many studies have 
been conducted in veterinary medicine with the same purpose of finding precipitating factors 
associated to seizures in dogs 20,39,40. The real mechanism by which precipitating factors may lead 
to seizures is still unknown. However, it is believed that these factors may change the normal 
homeostasis within the brain and therefore they may lower the seizure threshold, increasing the 
likelihood of seizures 41. 
Some studies suggested a relationship between oestrus cycle and epilepsy, stating that estrogens 
may reduce the seizure threshold, whereas progesterone may have an inhibition effect 28,42. Thus, 
there is an increase in seizure frequency both in periods when estrogens are mainly present or 
when progesterone is significantly decreased 28,42. In a study by Van Meervenne et al., an 
association was found between seizures and specific stages of the reproductive cycle 42. 
According to Van Meervenne et al., dioestrus and oestrus have been identified as important 
stages regarding epileptic seizures and this could be explained by the anti-convulsant effects of 
progesterone and the pro-convulsant effects of estrogens, respectively 42. This finding indicates  
that female neutered epileptic dogs might have a prolonged lifetime when compared with non-
neutered epileptic females 23,28,42. The effect of sexual hormones on seizure threshold has been 
discussed in humans as well 43. Nonetheless, neutered dogs tend to be less aggressive or 
hyperactive due to the declining rate of sexual hormones present in the organism, which may help 
controlling seizures, as hyperactivity and aggressiveness are considered as risk factors for 
triggering epileptic seizures 28. 
Stress can also be a precipitating factor, thus breeds that are known for being more active and 
anxious may be more vulnerable 44. A study analysed the relationship between seizures and 
possible precipitating factors in a group of dogs and stress was found to be strongly related with 
the occurrence of seizures within 24h after stress-related situations 39. According to Forsgard et 
al., stress-related situations possibly related with the occurrence of seizures in dogs with IE 
include sleep deprivation, emotional stress or changes in the average daily routine of the dog 39. 
The same factors are known to increase the likelihood of seizures in humans that have epilepsy 
as well 45–47. 
Weather conditions may be considered as a precipitating factor, however, there is little evidence 
in veterinary medicine. One study reported that nine of 50 of owners that replied to a questionnaire 
had identified weather conditions as a precipitating factor for seizures in their dogs 39. Conversely, 
studies in humans have reported a relationship between heat and cold temperatures and the 
occurrence of seizures, where patients identified heat and cold temperatures as being 
precipitating factors 45,46.  
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 PATHOPHYSIOLOGY OF EPILEPSY 
Epileptogenesis is described as the process of conversion of a regular neuronal activity into a 
hyperexcitable, disorganised and synchronised neuronal activity which persists for a non-specific 
period 8,10,48.  Trauma, brain infections/tumours, brain malformations, metabolic disorders or 
oxygen/glucose deprivation may disorganise the normal neuronal activity leading to 
hyperexcitability that triggers a seizure 48,49. The most frequent mechanism known for triggering 
seizures is the imbalance between excitatory and inhibitory neurotransmitters, with insufficient 
neuronal inhibition or excessive excitation 50. Abnormal concentration of specific ions can also 
lead to epileptiform events 50. A summary of alterations in the neuronal environment that may lead 
to abnormal neuronal discharge can be seen in Table 1.  
 
Table  1: Summary of alterations in the neuronal environment that may lead to seizures 
(Adapted from Sanders 2015). 
 
The concept of threshold is essential to understand the epileptogenesis. According to DeLahunta 
et al., a seizure threshold is considered as the minimum level of inhibition that when exceeded, 
may have the potential to originate an uncontrolled discharge of a particular group of neurons 51. 
A seizure occurs whenever this threshold lowers after any disturbance 51. Factors related with 
seizure threshold are illustrated in the Figure 1. 
In most cases, the epileptic focus initiates in neurons localised in the forebrain but may be 
originated in other parts of the brain as well 51. The cerebral cortex and hippocampus englobe 
groups of easily-firing neurons, which makes these regions the initial source for seizures in most 
of the cases 52.  
There is an individual susceptibility for epilepsy and it varies among dogs 8. In fact, under the 
same conditions, a dog with a lower threshold is more likely to experience an epileptic event 8 as 
a lower threshold will mean that the mechanism that balances the excitatory and inhibitory 
responses in the brain is less stable. Dogs with a lower threshold are more vulnerable to factors 
such as stress, exhaustion, oestrus and weather conditions 53. The same dog may experience 





Neuronal homeostasis (e.g. brain infections/tumours) 
Function of neurotransmitters 
Neuronal transmission, leading to the spontaneous firing of large groups of 
neurons (e.g. trauma) 
Glucose or oxygen metabolism 
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both focal and generalised seizures 8. Focal seizures arise from a specific area in the brain, 
whereas generalised seizures start in an epileptic focus, evolving to other regions of the brain 54. 
The neuronal environment is constituted by various elements that are intimately connected 
between each other and guarantee the normal homeostasis in the brain. If one of these elements 












The sodium – potassium adenosine triphosphatase pump (Na+K+ ATPase) is the main enzyme 
that composes this neuronal environment, responsible for the flow of sodium (Na+) and potassium 
(K+) across the neuronal membrane in an energy-dependent process 51. All these ions have their 
channels along the neuronal membrane, allowing them to freely move across it. Neurotransmitters 
may induce an excitatory or inhibitory response, being glutamate and GABA (Gamma-Amino-
Butyric Acid) the most essential excitatory and inhibitory neurotransmitter, respectively. 
Nevertheless, astrocytes also play an essential role in this environment by metabolising 
neurotransmitters and allowing the flow of neurotransmitters and ions through capillaries 51. 
Elements that constitute the neuronal environment are represented in the Figure 2. 
Figure 1: Factors that may affect the seizure threshold (Adapted from DeLahunta et al. 
2015). 




Figure 2: Neuronal environment constituted by different elements (Adapted from DeLahunta et 
al. 2015) 
 
Understanding the physiology behind the neuronal transmission is essential to understand the 
mechanisms underlying the pathophysiology of the epileptic events. Neurons are capable of 
communicating between them, receiving and integrating signs received from other neurons and 
transmitting information in the form of electrical signs 55.  
The neuronal membrane has a vital role in electrical transmission 55. This neuronal membrane 
separates two spaces, the intra and extracellular space, each one mainly constituted by several 
ions differently charged 7,55. During the resting membrane potential, the inner membrane is 
negatively charged, whereas the outer membrane is positively charged, mostly because of the 
presence of differently charged ions: Na+, K+ and chloride (Cl-) 55. In the absence of stimuli, the 
resting membrane potential is maintained along the neuronal membrane at a difference of -70 mV 
between inside and outside spaces 55. Regarding the resting membrane potential, many factors 
contribute for its maintenance such as the presence of energy-dependent Na+- K+ ATPase pumps, 
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the presence of ions with different concentrations/voltages and the permeability of the neuronal 
membrane to these ions 7,55. The K+ flow throughout the neuronal membrane profoundly 
influences the resting membrane potential because of the higher permeability to this ion 55. K+ 
moves quickly through K+ channels across the membrane by its concentration gradient and 
enables a dynamic balance 55. Concerning the extracellular space, Na+ and Cl- are the primary 
ions existing, whereas K+ ions are mostly concentrated in the intracellular space. Some anionic 
proteins within the neuronal cell can also contribute to a negative charge 55. The regulation of 
these ions is mainly controlled by astrocytes, which are the dominant subtype of glial cells that 
help in maintaining the normal homeostasis within the brain 56. These glial cells can work as 
buffers, regulating ions levels and metabolising neurotransmitters 7. 
The Na+- K+ ATPase pumps allows the flow of Na+ and K+ ions throughout the neuronal membrane 
and against their concentration gradients  7,55,57. This process is energy-dependent, requiring ATP 
as the primary source of energy that is provided by glucose metabolism and which represents the 
majority of the glucose consumption by the brain 55,58. Changes in the average concentration of 
serum glucose could lead to seizures because neurons do not have appropriate mechanisms to 
maintain glucose for metabolism purposes 55.  
As these pumps are a decisive factor to the normal function of neurons, many studies have been 
conducted to understand how alterations regarding Na+- K+ ATPase pumps can affect the 
neuronal activity 57,59. One study reported that abnormalities in the functionality of these pumps 
can trigger seizures 59.  
In the presence of a stimuli, neurons will depolarise leading to an action membrane potential that 
turns the intracellular space more positively charged than the extracellular space 55. 
Consequently, this action membrane discharge will progress along the neuron until it reaches its 
presynaptic terminal 55,57. Neurons are separated from each other by a synaptic cleft and in the 
presynaptic terminal, it is possible to find vesicles that are neuronal structures responsible for the 
storage and releasing of chemical substances denominated neurotransmitters 7. These 
neurotransmitters are an essential communication between consecutive neurons and depending 
upon the electric impulse generated, different neurotransmitters may be released 7. After the 
electric impulse reaches the presynaptic terminal, the ions channels will open and subsequently 
it allows the bonding between synaptic vesicles and the neuronal membrane in the presynaptic 
terminal 7. After bonding, these vesicles are stimulated to release a particular neurotransmitter to 
the synaptic cleft 7. Consequently, the released neurotransmitters will bond to specific receptors 
localised in the nearest post-synaptic neuron 7. 
The pathophysiology of seizures is complex and several factors have been credited as inducing-
seizures factors. Some studies reported the relationship between neurotransmitters and epilepsy 
where glutamate seems the excitatory neurotransmitter more involved in epileptogenesis 60–62.  
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In a healthy brain, excitatory and inhibitory mechanisms are balanced, which maintains a regular 
neuronal synchronisation and avoids the triggering of neurons without previous stimulating factors 
provided by other surrounding neurons 7. When triggered alone, these neurons may initiate an 
uncontrolled excitatory response that could lead to a seizure. An imbalance between inhibitory 
and excitatory responses may increase the likelihood of epileptiform activity if excitatory 
responses are over-represented 63. The simplest mode to inhibit an excitatory response is by 
releasing inhibitory neurotransmitters like GABA 52. Typically, an inhibitory response precedes an 
excitatory response and it is when inhibition mechanisms fail in controlling excitatory messages 
that neurons become hyper-synchronised, thus originating an epileptic focus 52.  
Glutamate is the most important excitatory neurotransmitter that is recycled by astrocytes and is 
ubiquitously distributed in the central nervous system (CNS) 8,50,56,64,65. Glutamate is obtained from 
glutamine that is converted into glutamate by glutaminase, a mitochondrial enzyme 52. Astrocytes 
have an important role in metabolising glutamate into glutamine, which is carried back to the 
presynaptic terminal to be reused 52.  
It is possible that glutamate is involved in the mechanism underlying epilepsy because there is a 
remarkable increase of glutamate’s concentration when a seizure occurs 8,56. The 
overconcentration of glutamate might be toxic, contributing to neuronal death by inducing 
alterations in permeability to calcium (Ca2+) ions 13,52,64,66.  Elevation of intracellular Ca2+ 
concentrations may lead to activation of certain enzymes such as proteases and phospholipases 
inducing proteolysis of proteins that constitute the neurons 62. Moreover, during neuronal death, 
glutamate is released to the extracellular space as it is present in most of the neurons 67,68. The 
resulting increase in extracellular glutamate overstimulates glutamate receptors especially the N-
methyl-D-aspartate (NMDA) receptor, which allows the entrance of calcium ions into neuronal 
cells through this receptor  67,68. The overconcentration of Ca2+ inside the neuronal cells will also 
contribute for oxidative stress and mitochondria’s damage 67,68. Neuronal death may expand the 
seizure focus increasing the likelihood of a seizure occurring and entering into a vicious cycle 
52,62. However, while it remains disputed as to whether neuronal death is a cause or a 
consequence of seizures, some people believe neuronal death could be both a cause and 
consequence.  
Several types of receptors differ by their agonist/antagonist function or their permeability to 
specific ions 7. According to Nakanishi, these receptors are involved in many cerebral functions 
such as synaptic transmission, brain plasticity, learning, memory, brain development and 
differentiation 69.  
Concerning glutamate, inotropic receptors are one type of receptor that work as a Ca2+ channel 
that only opens when bonded to an affinity-neurotransmitter, causing an opening that allows ions 
to flow through the receptor 63,70,71. These ionotropic receptors are related to a direct and faster 
response. NMDA is a subtype of ionotropic glutamate receptor and it has a high affinity to Ca2+ 
1. LITERATURE REVIEW 
9 
 
ions 62. The 5-methyl-4-isoxazole propionate (AMPA) receptor is another subtype of ionotropic 
glutamate receptor and it is related to fast excitatory responses 64. 
On the other hand, metabotropic glutamate receptors (mGluR) are closely related to the 
membrane and coupled to a G-protein 70,71. These receptors function as a second messenger 
system and when activated, they allow the flow of Ca2+ and Na+ ions which leads to depolarisation 
of neurons 63,70,71. Because it depends on secondary messengers, the response is slower when 
compared with ionotropic receptors 70. These receptors help to modulate the neuronal activity and 
they also regulate the releasing of neurotransmitters 64. Contrary to what happens with ionotropic 
receptors, mGluRs are activated in the presence of prolonged and increased concentrations of 
glutamate, which is relatively frequent after brain injury induced by seizures or trauma 72.  
GABA is synthesized from glutamate and it also has main receptors which are known as GABAA 
and GABAB 51,63,73,74. The former is an ionotropic receptor and the latter a metabotropic receptor 
and, as previously discussed, they have different mechanisms of actuation 73. The GABAA 
receptors allow the flow of Cl- ions, leading to hyperpolarization of neurons whereas GABAB 
receptors operate via second messenger system, increasing the conductance of K+ ions while 
decreasing the conductance of Ca2+ ions 75. Activation of both types of receptors leads to a 
hyperpolarization of neurons, therefore causing an inhibition of neurotransmission 63,75. 
GABA is known to be neuroprotective against distressing situations such as brain hypoxia and 
status epilepticus (SE), having an essential role on ceasing seizures 76,77. A study by Loscher et 
al., concluded that the neurotransmitter GABA was hardly found in cerebrospinal fluid (CSF) of 
epileptic dogs when compared with healthy dogs 78. Another study found that dogs with a low 
concentration of GABA in CSF appeared to develop antiepileptic drug (AED) resistance 79. Some 
studies suggest that either inhibition of GABA receptors or excessive activation of glutamate 
receptors may underlie the process of epileptogenesis 50,64,67,73. 
Epileptic seizures may aggravate over time, especially without proper treatment. Some 
mechanisms that may worsen epileptiform events have been widely studied. Kindling is one of 
those events, where repeated lower-intensity stimulus may induce spontaneous seizures by 
stimulating non-hyperexcitable neurons that are converted into a group of hyperexcitable neurons 
50,64.  It is possible that dogs develop epilepsy after experiencing spontaneously seizures because 
of this mechanism 80. The group of neurons that triggered the seizure will be considered as seizure 
focus 80. A study conducted by Goddard et al., concluded that discrete and lower-intensity 
electrical stimulation applied to some areas of mammalian brains overtime originated permanent 
alterations of brain function and lowered the seizure threshold, thereby increasing the likelihood 
of seizures with minimal stimulus 80. Another mechanism is known as mirroring and as stated by 
Dewey and Thomas, it is the process where a group of neurons from the opposite brain 
hemisphere are drafted into the seizure focus via the corpus callosum 50. Secondary focus 
originated through this previously process is called mirror focus 53. This mirror focus might be a 
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consequence of the kindling process and this secondary focus has the potential to generate 
seizures just as the primary source 80. 
Secondary brain abnormalities may result from seizures, mainly when occurring frequently and 
for an extended period. As referred previously, neurotoxicity resulting from overexcitation by high 
concentrations of glutamate may induce neuronal death 64,66,81. This disturbance of normal 
neuronal function may induce brain oedema with subsequent increase of intracranial pressure 
(ICP), which may decrease the normal perfusion of the brain 81. Therefore, the regular supply of 
energy and nutrients for neuronal cells is compromised, leading to anaerobic glycolysis, neuronal 
acidosis and neuronal dysfunction 81. In a study by Hasegawa et al., significant concentrations of 
glutamate were found in the CSF of epileptic dogs which suggests the relationship between this 
neurotransmitter and the pathophysiology of epilepsy 82. Similarly, increased concentration of 
glutamate was found in CSF of epileptic dogs 83, emphasising the theory that glutamate could be 
a possible biomarker for the diagnosis of IE. 
 
 CLASSIFICATION OF EPILEPSY 
Diagnosing epilepsy in dogs may be challenging for veterinarians considering the amount of 
different aetiologies and clinical manifestations involved. Therefore, an organised and detailed 
physical examination and signalment are necessary to ensure that noteworthy alterations are 
detected. A hemogram, routine serum chemistry and urinalysis are examples of simple and 
inexpensive exams that should be performed to exclude diseases that may mimic IE 11. IE should 
only be considered when significant abnormalities are not detected throughout physical 
examination and with a normal interictal neurological examination  34,49. In human medicine it was 
found that some types of epilepsy were possibly related to genetical abnormalities, resulting in 
changes of the existing classification regarding epilepsy by the International League Against 
Epilepsy (ILAE) 84. Many studies in veterinary medicine suggest genetical abnormalities 
underlying IE 24,30,85–87. These findings led to a new classification adopting the terms of StE, 





1. LITERATURE REVIEW 
11 
 
1.4.1 CLASSIFICATION OF EPILEPSY ACCORDING TO 
ITS AETIOLOGY 
 
Epilepsy can be classified according to its aetiology (Table 2). IE is classified as epilepsy of 
unknown cause when no other diseases are suspected 1 but recently IE has been divided into 
subgroups. According to these subgroups IE can be defined as purely genetic, which is usually 
related to channelopathies that are characterised by mutations in genes that encode K+, Na+, Ca2+ 
and Cl- channels 1,12 but it can only be confirmed by specific genetic tests 1. When in the absence 
of diagnostic tests that confirm genetic mutation, veterinarians should suspect of genetic-related 
epilepsy when the prevalence within a specific breed is higher than 2% 1. A causative gene has 
been already confirmed as responsible for epileptic seizures 1.  
Lastly, epilepsy can also be a consequence of any process that induces brain injury 1, being the 
latter defined as StE1. Typically, StE includes all the intracranial pathologies, regardless of 
aetiology. These pathologies can be either infectious, inflammatory, neoplastic, traumatic, 
vascular, degenerative or anomalous 1,7. The seizures associated with StE can also be defined 
as secondary seizures, as they are secondary to other disorders that had inflicted direct or indirect 
damage to the brain 13. 
 
Table  2: Epilepsy types defined by aetiology (Adapted from Berendt et al. 2015). 




Genetic Idiopathic Epilepsy 
Suspect Genetic Idiopathic Epilepsy 
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1.4.2 CLASSIFICATION OF SEIZURES ACCORDING TO 
LOCALISATION  
 
The cause of seizures can be located inside or outside the CNS 11. Causes of seizures according 
to its localisation are summarized in Table 3.  
Intracranial causes directly affect the CNS and are intimately related to the brain 11. Progressive 
brain disorders such as tumours, inherited diseases or inflammatory processes are defined as 
acquired epilepsy 11. Tumours are one of the leading reasons for seizures and most of the dogs 
with brain neoplasia frequently experience seizures 88. IE is defined by the occurrence of repeated 
seizures with an apparent unknown source and is also included in the intracranial causes 11. 
Considering  extracranial causes, toxins and metabolic disturbances are also responsible for 
epileptic episodes 11. Usually, epileptic episodes induced by intoxication or metabolic disorders 
are classified as reactive seizures because they are a physiological response to a temporary 
disruption of inhibition and excitation neuronal processes that are provoked by systemic disorders 
13,16,89. 
 
Table  3: Causes of seizures in dogs (Adapted from Berendt et at. 2015 and Lorenz et al. 2011)  
*Induce reactive seizures 
CAUSES OF SEIZURES IN DOGS  
INTRACRANIAL 
CAUSES 
Idiopathic epilepsy Genetic or unknown cause 
Acquired epilepsy 
Brain injury (e.g. trauma, cerebral vascular accident) 
Progressive brain disorders (e.g. tumours, inherited or 
inflammatory diseases) 






External (e.g. carbamates, lead poisoning, ethylene 
glycol, metaldehyde, permethrins, mycotoxins, chocolate, 
metronidazole, organophosphates) 
Internal, associated with a metabolic disease or organ 




Hypoglycemia, hyperglycemia, electrolyte disorders, 




1. LITERATURE REVIEW 
13 
 
1.4.2.1 BRAIN DEVELOPMENT DISORDERS 
 
Some brain abnormalities may happen during the normal development of dogs and even though 
it is not as common as other causes of seizures, they can be included in the possible differential 
diagnosis, especially when in the presence of some breeds like toy breed dogs 63,90. For instance, 
chihuahua dogs are known for having a higher predisposition for congenital hydrocephalus and 
this disease is the most commonly diagnosed brain development disease that may induce 
seizures 63,90. Most of the brain development diseases are severe, so generally it is possible to 
find abnormalities on the neurological examination such as proprioceptive deficits and visual 
impairment 63. Ataxia is also a common sign observed in dogs with brain development diseases 
90. These brain development disorders are normally seen in young dogs and imaging diagnostic 
exams like MRI and computed tomography scan (CT-scan) are of great value to detect these 
structural dysfunctions in the brain 91. 
 
1.4.2.2 BRAIN INJURY  
 
In humans, acquired epilepsy is normally a result of brain injury 92. Brain injury is life-threatening 
and usually is a consequence of direct head trauma caused by car accidents, gunshot, falls or 
blows inflicted to the head 92. In other circumstances, brain injury can be the result of a cerebral 
vascular accident (CVA) that in most cases is a consequence of thrombosis, haemorrhage or 
embolism 93. Nevertheless, CVA is not as common in dogs as in humans 93. Brain injury may be 
reversible or not, depending upon its severity. The likelihood of developing seizures after brain 
injury will be higher the more severe the injury 92. In situations where skull fractures are presented, 
the chances of developing epilepsy as a result of brain injury are higher 92. Brain injury alters the 
brain homeostasis, which deregulates the physiological mechanisms of inhibition and excitation 
and consequently originating seizures 93,94. Currently, it is difficult to predict whether a dog that 
suffered a brain injury will develop seizures in the future, but owners must be aware that chances 
are higher in such cases. Seizures might occur within an extended period after brain injury 
episode and pharmacological therapy should be prescribed as soon as seizures appear 94. 
 
1.4.2.3 PROGRESSIVE BRAIN DISORDERS 
 
Brain tumours are known to be the most common causes of progressive brain disorders 92. Brain 
tumours are a common condition that may affect dogs of all ages but usually is more common 
amongst elderly dogs 63. Brain tumours can be primary or secondary (e.g. metastasis from 
another tumour) and they can start seizures by inducing compression on the surrounding brain 
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tissues, which may disorganise the usual structures and also prevent the normal blood flow in the 
vessels 63. Veterinarians should suspect brain tumours whenever elderly dogs are presented with 
seizures, especially when it is the first onset 95. In some cases, seizures are the first symptom 
showing up in dogs with brain tumours 95. When a brain tumour is suspected, imaging diagnostic 
exams should be performed to detect these abnormalities in the brain. MRI is usually the best 
diagnostic tool available for diagnosing tumours because of its high sensitivity and specificity for 
soft tissues 63. Veterinarians should be aware that dogs with brain tumours or other intracranial 
lesions may have an unchanged neurological examination 96. According to Ghormley et al., the 
neurological examination had 74% sensitivity and 62% specificity on previewing StE 96. 
Inflammatory brain diseases are also a common cause of seizures, especially in non-vaccinated 
young dogs. All inflammatory processes have the potential to start seizures whenever 
neuroinflammation is presented. Many inflammatory diseases may induce brain inflammation, 
whether they are infectious or not. Inflammation-related with bacteria (e.g. ehrlichiosis), virus (e.g. 
distemper and rabies), parasites, protozoa (e.g. toxoplasmosis and neosporosis) or fungi (e.g. 
cryptococcosis) are relatively common in young animals, but these diseases may affect dogs of 
all ages 63. Generally, seizures are not the first sign of inflammatory processes induced by 
infectious agents, but they are common in dogs in chronic stages 63. Nonetheless, seizures might 
be the first and only clinical sign in diseases like toxoplasmosis or neosporosis 63. Veterinarians 
should suspect inflammatory diseases whenever young dogs are presented with seizures, usually 
without a proper vaccination protocol, with other systemic signs and with remarkable alterations 
on the neurological examination 97. Systemic signs may vary depending upon the aetiology, but 
gastrointestinal disturbances such as vomiting and diarrhoea, cough and anorexia are the most 
commonly observed 97. Generally, neurological deficits are non-specific, so further thorough 
examination is necessary. As inflammatory diseases are progressive, it is expected that clinical 
signs worsen along time without treatment. For a dog who has been having seizures for an 
extended period, without any abnormalities detected in the interictal period, the cause of the 
seizures is unlikely to be inflammatory 97.  
Non-infectious inflammatory diseases inducing seizures are less common than infectious 
inflammatory diseases 63. The most common non-infectious inflammatory disorders in dogs are 
granulomatous meningoencephalitis (GME) and the necrotising meningoencephalitis (NME), 
affecting dogs of all ages. However, there is a higher prevalence of NME in younger dogs 63,97. 
Ideally, analysis of CSF is advised when inflammatory processes are suspected and serology or 
polymerase chain reaction (PCR) should be performed whenever an infection is suspected 63,97. 
Imaging diagnostic exams such as CT-scan or MRI should be performed as well, whenever 
appropriate. A definite diagnosis of non-infectious inflammatory diseases can be only made by 
histopathology, so a diagnosis in life is not possible 97. 





One study reported that intoxications and hypoglycaemia were the most frequent causes leading 
to reactive seizures 98. Intoxications may lead to seizures by changing the normal 
excitatory/inhibitory mechanisms or interfering with the metabolism of neurons 99. Toxins may 
increase excitatory processes within the neuronal environment by acting on excitatory 
neurotransmitters 100. Conversely, toxins also act in inhibitory receptors, leading to an inhibition 
of these same receptors 100. 
 
1.4.2.4.1 EXTERNAL TOXINS 
 
Intoxication may increase the risk of developing a SE and the risk is higher when compared with 
dogs with concomitant idiopathic epilepsy 14. Usually, intoxications have an acute onset and 
systems like cardiovascular, gastrointestinal or urinary are affected, triggering systemic 
abnormalities together with neurological deficits 101. Depending upon the toxin, clinical 
manifestations may vary but neurological and systemic abnormalities are typically presented at 
the same time 102. When left untreated, clinical signs may worsen within hours, leading ultimately 
to death. Unless in the presence of an aggressive SE, dogs with IE will not experience their health 
deteriorating so rapidly compared to an intoxication 102. According to Zimmermann et al., 
intoxications with organophosphates and insecticides appeared to be the most common amongst 
dogs 101. These toxins inhibit the action of acetylcholinesterase in the cholinergic synapses, which 
destabilise the normal homeostasis of the neuronal environment 101. Rodenticides are another 
common cause of intoxications in dogs. Crimidine is a common rodenticide widely available and 
it is considered as a pro-convulsant because it acts as a vitamin B antagonist, which is essential 
for the synthesis of GABA and also inhibits the action of acetylcholinesterase 101,103. Intoxication 
with permethrins is relatively common in cats because these insecticides are highly toxic for this 
species for reasons yet unknown 104. Permethrin toxicity mainly happens when topical spot-on 
products formulated for dogs are applied in cats 105. Clinical signs related to toxicosis are mainly 
neurological due to the effects of permethrin in the presynaptic nerve ending  105,106. Intoxication 
with permethrins leads typically to an aggressive SE and most of the cats die when not treated.  
 
1.4.2.4.2  INTERNAL TOXINS 
 
Many metabolic disorders may be responsible for the occurrence of seizures in dogs, but most of 
the cases are reversible with the appropriate treatment. Metabolic-related disorders are a 
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common cause of seizures in dogs and are provoked by the accumulation of endogenous toxins 
in the organism 92,99. 
Alterations in average blood glucose are one of the most common causes of reactive seizures in 
dogs and hypoglycaemia is more frequently seen in these same dogs 98. Seizures induced by 
hypoglycaemia should be suspected whenever blood glucose levels are repeatedly low, 
especially after seizures and when seizures are reversed by glucose supplementation 98. 
Hypoglycaemia may lead to a seizure due to the lack of glucose, which is the primary energy 
source for energy-dependent metabolisms occurring in the brain 99. Generally, neoplasia is the 
most common cause for persistent hypoglycaemia and imaging exams such as abdominal 
ultrasound or CT-scan should be performed to rule-out this diagnosis. Insulinoma is the most 
common pancreatic neoplasia that affects beta cells which are responsible for insulin production, 
causing an overproduction of this hormone, therefore inducing hypoglycaemia 107. Insulinoma 
should be suspected whenever an elderly dog is presented with seizures 107. Hypoglycaemia may 
also be a consequence of inadequate production of glucose due to hepatic failure, so it should 
also be considered during the diagnosis 99.  
Hepatic encephalopathy (HE) is a metabolic disorder normally provoked by the existence of a 
portosystemic shunt that is typically associated with either congenital or acquired hepatic 
abnormalities 108,109. HE develops when abnormal levels of ammonia are presented in the blood. 
Ammonia is highly liposoluble and can easily cross the blood-brain barrier (BBB), therefore 
leading to alterations of normal brain homeostasis 108. When in the presence of a portosystemic 
shunt, ammonia is not converted into urea, that is water-soluble and less toxic, going directly to 
the systemic circulation without being metabolised by the liver 108. HE is relatively common in 
dogs and one of the most common metabolic causes of seizures in Yorkshire Terriers dogs 108 
Uremic encephalopathy (UE) is another common metabolic disorder that is closely related to renal 
failure 99. Usually elderly dogs are the most affected however it can be seen in young dogs 
especially in cases of acute renal failure. Seizures may be a sign of renal failure when in the 
presence of high levels of urea in the blood, due to a compromised excretion of this metabolite in 
the urine 99. An imbalance of acid-base homeostasis and electrolytes concentration as a 
consequence of renal failure are also a cause for seizures 99. 
 
1.4.3 CLASSIFICATION OF SEIZURES ACCORDING TO 
THEIR PRESENTATION 
 
Seizures can be classified according to their presentation, which allows a better understanding of 
affected areas of the brain as well as their severity 63. Depending upon the affected areas of the 
brain, the clinical manifestation will vary and even with the same affected area, different dogs may 
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express different signs 63. Even though impairment of consciousness can be detected in some 
situations, this evaluation is not as accurate as in humans because it relies on owners reports, 
which sometimes may not be precise 1. There is no reliable scientific evidence supporting a 
relationship between clinical manifestations and aetiology of the source 8. Classification of 
seizures according to its presentation may not influence the treatment but it may help not only 
identifying which region of the brain is possibly affected but also it allows the perception of whether 
there is improvement associated to treatment and progression of the disease 3.  
 
1.4.3.1 FOCAL EPILEPTIC SEIZURES 
 
Focal epileptic seizures (FES) are originated by abnormal electrical activity in a localised, specific 
group of neurons within one cerebral hemisphere and their clinical presentation may help to 
identify the affected areas of the brain 1. Focal seizure rises from an epileptic focus, but the 
abnormal electrical activity is not propagated to the other cerebral hemisphere 63. Depending upon 
the localisation of the epileptic focus, any region of the body may be affected 52. FES are more 
likely to occur in the presence of StE as a consequence of other diseases, which emphasises the 
importance of searching for these diseases when in the presence of FES, especially if 
consciousness stays unchanged 4,35,37,63. This presentation usually manifests into a motor and 
focal muscle activity that begins laterally 1. FES can also be present as autonomic or behavioural 
and these presentations may coexist with motor presentation 1. FES may initiate after a sensory 
experience like lights, smells, sounds or touch 102. These seizures may pass unnoticed by owners 
or can be misinterpreted as behavioural abnormalities 110.  
 
1.4.3.2 MOTOR FOCAL EPILEPTIC SEIZURES 
 
This type of presentation is mainly characterised by involuntary, unilateral focal motor episodes 
that result in atypical movements of specific muscles, such as facial twitches, head movements 
(e.g. flexion/extension), contraction of masticatory muscles or facial jerking 1,9. Some of these 
signs may be defined as hyperkinetic when there is an involuntary contraction of a group of 
muscles of one side of body, which may lead to an abnormal posture and dislocation of the midline 
3.  
On the other hand, hypokinetic signs are described as sudden atonia in a group of muscles, which 
may lead to falls 3. It is believed that this type of seizures might start from an epileptic focus that 
is near to a primary motor area in the frontal cortex 9.  
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1.4.3.3 AUTONOMIC FOCAL EPILEPTIC SEIZURES 
 
In this type of presentation, it is possible to observe autonomic signs such as mydriasis, 
hypersalivation, urination, defecation or vomiting 1,110,111. Other less visible signs like salivary 
gland enlargement, dysphagia or oesophageal spams may be associated with autonomic focal 
seizures 112,113.  These autonomic signs may be associated to injured areas in the limbic system 
3. 
1.4.3.4 BEHAVIOUR FOCAL EPILEPTIC SEIZURES 
 
In humans, this type of presentation is characterised by psychic and sensory episodes, where 
people experience sensations such as agitation, fear, anger or anxiety 114. According to the ILAE, 
focal onset can be subclassified as non-impaired or impaired awareness, depending on whether 
consciousness is impaired or not 115. In dogs, the evaluation of behaviour changes and 
consciousness is difficult to assess since it is based only on the owners reports or video-
documentation 110.  
For this reason, the International Veterinary Epilepsy Task Force (IVETF) decided that FES 
should not follow the same classification used in humans since it is difficult to do an accurate 
evaluation of these alterations 1. Nonetheless, some studies have reported behaviour changes in 
dogs associated with focal seizures such as anxiety, seeking/attention or avoidance behaviour, 
confusion, fear, fatigue, bitting or licking imaginary objects and compulsive tail-chasing 110,111,116. 
 
1.4.3.5 GENERALISED EPILEPTIC SEIZURES 
 
Generalised epileptic seizures (GES) are described as the most common presentation in dogs 
and indicates that both cerebral hemispheres are affected 1,11,117. In contrast, other studies 
suggest focal seizures as the most common 26,28. This opposition may be related to many factors 
such as discrete clinical manifestation, non-agreement between veterinarians regarding seizure’s 
classification, lack of experience or population bias.  
In GES, epileptic activity may propagate from an epileptic focus to other parts of the brain and 
other groups of neurons may be affected 1. This presentation usually reveals itself as a tonic-
clonic muscle activity that begins bilaterally, often symmetrical and usually consciousness is 
impaired 9,63. However, GES can also be present as only clonic, tonic, atonic and myoclonic but 
these presentations are less frequent  1,63. There may be cases where consciousness stays 
unmodified during GES 1. However, evaluation of consciousness in dogs is complicated because 
they cannot express their experiences as humans do 49. Because of little use of 
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electroencephalogram (EEG) recordings in veterinary medicine, the correct classification should 
rely on the differentiation between a focal and generalised seizure and more complex 
classifications are not useful and may be confusing 49. Normally, GES will follow a particular 
pattern for a specific dog but may vary between different dogs 3.  
Frequently, autonomic signs are noticed during GES and defecation, urination and 
hypersalivation the most commonly observed 1. According to the IVETF, GES is identified in the 
presence of both clinical and EEG changes demonstrating possible affection of both sides of 
cerebral hemispheres 1. A generalised seizure is precepted by owners as a potentially life-
threating condition for their pets when compared with a focal seizure, which can remain unnoticed 
most of the time 32. Most of the owners believe that generalised seizures decrease the quality of 
life (QoL) of their pets, which could lead to premature euthanasia if owners are not available to 
cooperate in the diagnosis and treatment 3. Furthermore, they can easily detect a generalised 
seizure rather than a focal seizure 32. 
 
1.4.3.6 GENERALISED TONIC-CLONIC EPILEPTIC SEIZURES 
 
This type of presentation was formerly called grand mal seizures because of its generalised, 
aggressive muscle movements 111,117. There is a high variability on the duration and clinical 
manifestations of these episodes 9. Generalised tonic-clonic seizures may cease in less than five 
minutes but the majority of them do not persist for more than one minute 3. 
The tonic phase associated with this presentation is characterised by a generalised muscle 
contraction and increase of muscle hardness, which leads to opisthotonos that generally does not 
last more than one minute 1,9,63. Before this stage starts, there is a loss of consciousness 9. 
According to Lorenz et al., consciousness may be measured through responsiveness, 
attentiveness and disorientation 63.  
The clonic phase follows the tonic phase and is characterised by rhythmic, repetitive contractions 
of the muscles, that leads to jerking and chewing movements of limbs and jaw, respectively 9,11. 
Some dogs may experience specific movements such as running or may vocalise 9. During the 
seizure, tonic and clonic phase may alternate after one another 9. Autonomic signs are relatively 
common during a generalised tonic-clonic seizure and hypersalivation, defecation or urination are 
normally observed 9.  
In the post-ictal phase, dogs may experience abnormal behaviour such as confusion, 
aggressiveness, fear or anxiousness 9. Also, it has been reported that some dogs might have 
proprioceptive deficits, temporary blindness and ataxia 9. If neuronal deficits persist for more than 
24 hours after the epileptic episode, one should suspect of StE 63. 




1.4.3.7 GENERALISED TONIC EPILEPTIC SEIZURES 
 
In this type of presentation, dogs experience an increase in muscle hardness but without being 
followed by a clonic phase 9. Just as generalised tonic-clonic seizures, loss of consciousness and 
autonomic signs may also occur 9. Pre and post-ictal signs usually are similar to other 
presentations and generally it only lasts for seconds 3,9. 
 
1.4.3.8 GENERALISED CLONIC EPILEPTIC SEIZURES 
 
Clonic seizures are characterised by involuntary and repetitive contractions of the same group of 
muscles, which are often aggressive and intense 1,9. Consciousness is also impaired and 
autonomic signs are similar from the ones observed in other presentations 3. 
 
1.4.3.9 MIOCLONIC EPILEPTIC SEIZURES 
 
Clinical manifestations associated with this presentation include repetitive myoclonic jerking of 
some muscles of the head, neck and thoracic limbs and these movements are generally abrupt 
118. It can happen as a response to a visual, sound or light stimulus 119. Normally, these muscles 
spasms are bilateral, symmetrical and rhythmic 3.  According to Sanders, consciousness is not 
impaired in most of the times, which may lead to a misclassification as focal seizure 3. Some 
studies reported the presence of this type of presentation in miniature wirehaired dachshunds, 
basset hounds and beagle dogs, associated with Lafora disease 120–122.  
 
1.4.3.10 ATONIC EPILEPTIC SEIZURES 
 
Previously known as petit mal, atonic seizures are the least frequent of all presentations 63. This 
type of presentation is characterised by a sudden loss of muscle tone, together with a loss of 
consciousness 3,63. This atonia may persist for several minutes until the dog is able to recover 
from it 3. Given that clinical manifestation is very tenuous, this presentation might pass unnoticed 
by owners 3.  
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1.4.3.11 FOCAL SEIZURES WITH SECONDARY 
GENERALISATION 
 
Sometimes, a focal seizure can evolve into a generalised seizure when the abnormal electric 
activity spreads from the epileptic focus to the bilateral neuronal environment 1. Generalised 
seizure can evolve from a focal seizure within a short space of time, so focal seizures may stay 
unnoticed, leading to misclassification as a generalised seizure 9. This type of presentation will 
start with a focal seizure that may present motor, behavioural or autonomic signs and will suddenly 
progress to a convulsive phase with bilateral tonic-clonic, clonic or tonic movements, with loss of 
consciousness 1. Classification of seizures according to their presentation can be observed on 
Table 4. 
Table 4: Epilepsy classification by seizure semiology (Adapted from Berendt et al. 2015). 








Unilateral and regional signs 
such as motor, autonomic or 




Focal motor event (e.g. muscles 
twitch repeated jerking movements, 
rhythmic blinking, twitching of 
specific group of muscles 
Autonomic 
Parasympathetic influence (e.g. 
dilated pupils, urination, defecation, 
hypersalivation 
Behavioural 
Changes in normal or expected 
behaviour depending on 
breed/species/personality (e.g. 







Bilateral signs can be either 
tonic, clonic, tonic-clonic, 
myoclonic or atonic (rare) 
Tonic 
Muscle hardness and contractions 
lasting seconds to minutes 
Clonic 
Regularly repetitive contractions 
from the same muscles groups and 
can be rhythmic 
Tonic-
Clonic 
A sequence starting in a tonic 
followed by a clonic phase 
Myoclonic 
Involuntary contractions that can be 
either single or multiple (a specific 
muscle or a group of muscles) 
Atonic 
Abrupt loss or decrease of muscle 
tone and can involve different 
groups of muscle. It can be 
misunderstood as a syncope 




According to Sanders, 85% of the focal seizures in dogs later progress to generalisation 3. The 
duration of a focal seizure is generally concise and lasts seconds to minutes, followed by a 
secondary generalised seizure 1.  
Owners are less likely to witness the focal seizures, which emphasise the importance of an 
accurate report by owners to help the veterinarian on the right approach 9. As pointed out by 
Berendt and Gram, most of the focal seizures evolve to secondary generalised seizures 117. 
 
1.4.4 CLASSIFICATION OF SEIZURES ACCORDING TO 
THEIR CHRONOLOGICAL DISTRIBUTION  
 
Prodrome is the phase that precedes the seizure and it is the first manifestation that can be seen 
by owners. Generally, during prodrome, dogs experience behaviour changes like anxiousness, 
increased vocalisation, seeking/attention behaviour, fatigue or chewing unusual objects 1,3,50. 
Prodrome phase signs are variable and it may last from hours to days previous to the epileptic 
event itself 1. There may be behaviour changes that are easily detected by the owner for being 
uncommon in their pets, which may help to detect the onset of an epileptic episode. On the other 
hand, these changes can remain unnoticed by owners 3. According to Berendt and Gram, 
prodromes typically reflect an increase of excitability in an epileptic focus or in the entire brain, 
just before the ictus phase 117. In humans, the prodrome is described as a mood change that 
happens minutes to days before the epileptic episode and no significant changes are normally 
detected on EEG 3. The prodrome phase can be misclassified as a behaviour focal seizure, but 
the latter tends to be shorter in time compared with the former 1. Generally, this phase can pass 
unnoticed because most of the owners will not think these behaviour abnormalities as something 
pathological, especially if associated to the first episode of seizures 50. 
There is a small phase between the prodrome and ictal phase called aura 63,117. This phase may 
be hard to identify and distinguish from prodrome because both involve behaviour changes, but 
generally the aura may also involve autonomic and motor changes, lasting for seconds to minutes 
63,117. Therefore, the aura phase is an early manifestation of the seizure 9. According to the new 
classification by the ILAE in humans, the aura is classified as a focal seizure mostly because 
some noteworthy changes are detectable on EEG  84.  
Ictus is the phase when the seizure occurs, which may consist in the different types described 
previously 1,117. The ictus phase may last from seconds to minutes and there is a high variability 
of manifestation amongst dogs 3. The damage provoked by seizures is in part related with the 
length of the episode, so the longer the seizure, the higher probability of secondary lesions. These 
secondary lesions are mostly a consequence of prolonged muscles contractions, apnoea, 
metabolic disorders, hypertension and hyperthermia 3.  
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The post-ictal phase comes just after ictus and dogs may appear confused, disorientated, ataxic 
or may urinate and defecate 1,9. Also, some neurological deficits can be detected during the post-
ictal phase such as decreased or absent menace response and temporary blindness 9. The post-
ictal phase may vary amongst dogs in duration and clinical manifestation 9. Some dogs may 
rapidly recover from it within seconds to minutes while others may have clinical signs associated 
with the seizure lasting for hours to days 3. It is during this phase that the normal brain function 
returns progressively 9,11. In one study, visual impairment and excessive alertness were found to 
be the most common detected abnormalities during the post-ictal phase 123. In other study with 
125 epileptic dogs, the most observable signs during the post-ictal phase were fatigue, abnormal 
hunger or thirsty, mydriasis and disorientation, which lasted from minutes to hours 37. It seems 
that there is no connection between aura/post-ictal phases and severity/aetiology of the seizures 
3,117. 
After the post-ictal phase, the interictal phase begins. According to Sanders, it is described as the 
space of time between the end of the post-ictal phase and the beginning of the next ictus 3. This 
phase is important in dogs that experience seizures frequently 3. During this phase, dogs may 
demonstrate some proprioceptive deficits and behaviour abnormalities 3. When a dog 
experiences a prolonged and aggressive ictus, it can consequently result in brain damage which 
may be reflected in prolonged or permanent post-ictal or interictal abnormalities 3. If these 
neurological deficits persist for more than 5 to 7 days after an epileptic seizure, a structural brain 
injury should be suspected 3.  
 
1.4.4.1 STATUS EPILEPTICUS 
 
SE is defined as a severe and life-threating condition that usually involves generalised tonic-clonic 
seizures that are more intense and long-lasting 13. SE is the term used to describe an epileptic 
episode that lasts longer than five minutes or when two or more seizures occur successively, 
without any recovery between them  13,63. Usually, physiological mechanisms within the brain are 
capable of stopping seizures, but when these mechanisms cease, SE ensues 53.  In one study, 
the prevalence of SE within a group of dogs that were hospitalised was 0.7% 14. The greater the 
frequency and the longer the duration, the more severe is the injury, increasing the chances of 
brain injury and systemic abnormalities 13,124. Severe forms of epilepsy characterised by recurrent 
SE and cluster seizures were associated with some breeds like Border Collies and Australian 
Shepherds 30,125. Most of the episodes of SE in dogs are related to StE provoked by different 
causes such as tumours, encephalitis or trauma 126. In one study, 45.1% of dogs that suffered SE 
as their first manifestation of seizures were diagnosed with StE 14. 
SE is considered as an emergency that should be seen immediately by a veterinarian, to avoid 
possible neurological damage as consequence of some dysregulations like hypoglycaemia, 
1. LITERATURE REVIEW 
24 
 
hyperthermia, acidosis, renal failure or cardiopulmonary failure following the event 14. SE may be 
associated with IE, however it can also be involved in other disorders such as infections, trauma, 
toxins, neoplasia, metabolic or vascular diseases 127. Thereby it is essential to realise a thorough 
examination to exclude these differential diagnoses. Intoxications may lead to SE in most of the 
cases, regardless of the type of toxins and it is a common diagnosis in dogs that are experiencing 
their first SE 14.  
In a study by Zimmermann et al., dogs with IE were less likely to develop SE when compared with 
dogs that had StE 14. It appears that dogs that suffer from epileptic seizures arising from a 
secondary disorder are more likely to develop SE than dogs that are affected by a primary disorder 
such as IE 13,35. Also, according to Platt and Haag, almost half of the dogs that experienced SE 
had not experienced any seizure beforehand 13. This finding supports the hypothesis that SE may 
be more related to StE rather than with IE. Nonetheless, it appears that SE may be associated 
with AEDs failure to control seizures in dogs with IE 4.  
There is no risk factor such as sex or age associated with a higher prevalence of SE 128,129. As 
stated by Arrol et al., dogs with IE that experienced SE have a worse prognosis compared with 
those who have IE but did not experience SE 130. Most of the deaths related to episodes of SE 
were a result of euthanasia 131. Euthanasia is frequently performed in dogs with uncontrolled SE 
or cluster seizures, mainly due to lack of financial conditions or cooperation by owners 132. 
Although less common, euthanasia may also arise due to lack of experience of veterinarians, who 
may feel frustrated in chronic and non-responsive to treatment cases 126. 
When assessing a patient in SE at the hospital, the main goal of treatment is to stop seizures 
because prolonged SE may induce functional changes that may be damaging for the brain. It is 
crucial to ensure that airways, breathing and cardiovascular function are safeguarded 53. Also, 
blood pressure, temperature and blood glucose should be measured as soon as possible to allow 
early detection of abnormalities 53. After ensuring the airways-breathing-circulation (ABC), 
catheterisation should be performed so fluids and intravenous (IV) drugs can be administered 
rapidly, therefore allowing higher serum concentrations 126.  
Initially, benzodiazepines (BZPs) are the first drugs of choice for the management of SE because 
of their fast-action 129. When intravenous access is not available, BZPs may be given 
intramuscular (e.g. midazolam) or intrarectally (e.g. diazepam (DZP)) in an attempt to stop 
seizures 129. DZP is the first-choice drug used in the treatment of SE and it can be given either IV 
or intrarectal 133. DZP is mainly used by owners at home, in emergency cases. Administration of 
intranasal midazolam is becoming a promising alternative option for home-treatment. In a study 
by Charalambous et al., midazolam given intranasally at a dosage of 0,2 mg/kg seemed to be 
more effective than DZP given via-rectal 134.  DZP is given intravenously in a dosage of 0,5 to 2 
mg/kg, which may be repeated twice or three times 53,63. It is advised to double the dosage of DZP 
in case of dogs that are undergoing a chronic treatment with phenobarbital (PB) because the 
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standard dosage of DZP may not be enough to control seizures 133. When a IV route is not 
available, DZP should be given intrarectal at a dosage of 1-2 mg/kg 126. If seizures keep occurring, 
additional boluses of BZPs may be necessary 53. A constant rate infusion (CRI) may also be a 
good option, especially because it enables a continuous serum concentration and the 
recommended dosage of DZP as a CRI is 0,25-0,5 mg/kg/h 63.  
Generally, BZPs are not effective in controlling chronic cases of SE because of pharmacological 
resistance 129. The duration of action of BZPs is short, so in most of the cases, maintenance with 
stronger AEDs such as PB is required 53. For dogs that are not undergoing treatment with PB, a 
loading dosage may be needed 53. The loading dosage recommended of PB in dogs is 15 mg/kg 
and should be given IV slowly and diluted with sterile saline solution during five to ten minutes 126. 
PB can be concurrently administered with DZP and the recommended dosage is 2-4 mg/kg given 
IV every 20 to 30 minutes until it reaches a total of 18-20mg/kg 53. At that point and if seizures 
stopped, a maintenance dosage of 3-5 mg/kg of PB should be given IV every 12 hours for 24 to 
48 hours 53. If the dog recovers its consciousness and capability to properly swallow, oral AEDs 
may be given 53. If seizures persist, administration of stronger AEDs such as levetiracetam in a 
dosage of 20-60 mg/kg may be required 126 
When any of these AEDs do not control seizures, boluses of propofol in a dosage of 4-6 mg/kg 
IV is recommended and additional precautions should be taken to avoid apnoea  63,129. According 
to Sanders, a CRI of propofol should be administered following the first boluses in a rate of 6-10 
mg/kg/h 126. According to Lorenz et al., CRI administrations of DZP or propofol should continue 
for six to eight hours 63. If CRI succeeds in controlling seizures, the rate of infusion should be 
lowered to the lowest rate that allows effective control of seizures 63. Ketamine is also an option 
and may be given IV in a dosage of 5 mg/kg 126. In one study, a bolus of ketamine at a dosage of 
5mg/kg IV followed by a CRI of this same drug at a rate of 5mg/kg/h was successful in controlling 
seizures in a dog that was unresponsive to both DZP and propofol 135. 
As a last resort, when any of the previously mentioned drug fails in controlling seizures, coma 
should be induced with pentobarbital at a dosage of 5-15 mg/kg given IV until it reaches the 
desirable effect 126. In this situation, artificial ventilation should be implemented as well as 
maintenance of blood pressure to avoid hypotension 126.   
Monitorisation and intensive supportive care of the epileptic patient are important to ensure that 
complications do not occur. Some standard blood tests such as hemogram or serum chemistry 
should be performed, especially blood electrolytes with the aim of detecting electrolyte imbalance  
129. When intoxication is suspected, toxicity screen tests should be done 129. Hypoxia and 
hypotension are likely to happen after seizures, so it is crucial to ensure a proper monitorisation 
of these two parameters with pulse oximetry and oscillometer, respectively 129. If the animal is 
hypoxic, oxygen may need to be supplemented by face masks or nasal cannula 63. Frequently, 
hyperthermia occurs secondary to seizures, so it is essential to cool down the patient through 
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fluids and active cooling  126,129. Analysis of arterial blood gases is another vital exam that should 
be performed to detected metabolic acidosis as a consequence of the seizures 129. 
Hypoglycaemia may be a cause of seizures, so supplementation with 5% dextrose fluid should 
be done intravenously 129. Hyperglycaemia induced by glucose supplementation may be 
damaging to the brain if hypoxia is present, so thiamine (vitamin B1) should be given 
intramuscularly before administering fluids supplemented with glucose 129. During brain hypoxia, 
there is a persistent anaerobic metabolism over aerobic metabolism due to oxygen deprivation 
136. An overload of blood glucose will contribute for a hypermetabolism that will prefer anaerobic 
over aerobic metabolism 136. Thiamine is an important coenzyme in oxidative metabolism, thus 
will contribute for a higher utilisation of this energy pathway 137 . 
Dogs that experience SE or cluster seizures are likely to develop cerebral oedema as a 
consequence of severe seizures so that mannitol may be an option for treatment  53. Dogs with 
severe neurological deficits such as coma or stupor may need intubation and artificial ventilation 
63.  
1.4.4.2 CLUSTER SEIZURES 
 
According to Sanders, the term cluster seizures refers to an abnormal sequence of seizures in 
the same individual 3. Cluster seizures are characterised for being a sequence of several 
successive seizures where the dog recovers to its normal status between each episode 3. 
Therefore, cluster seizures differ from SE because, in the latter, dogs do not recover between 
episodes 3. These cluster seizures may be a group of multiple seizures that occur within different 
spaces of times going from days to months 3. German shepherds and Boxers seem to be more 
likely to suffer from cluster seizures than other breeds 131. In a study, dogs with cluster seizures 
were more likely to be diagnosed with structural brain disease  33. Similarly, according to Pákozdy 
et al., a diagnosis of StE was likely when in the presence of cluster seizures 35. 
 
 DIAGNOSIS 
There is no standard gold test that can be used in the diagnosis of epilepsy 18. For well-
understanding of the seizure type, clinicians are enforced to get an appropriate clinical history as 
also a general detailed examination of the animal. A diagnosis of IE is achieved whenever other 
possible causes of seizures are excluded 12. The underlying cause of seizures can be assessed 
by a thorough clinical history, physical and neurological examination and diagnostic exams that 
should be performed based on the main differential diagnosis 6. Preferably, extracranial causes 
should be ruled out first and then more specific exams such as MRI or CT-scan should be 
performed to exclude intracranial causes 63.  
1. LITERATURE REVIEW 
27 
 
Ideally, some elementary exams such as hemogram, serum chemistry and urinalysis should be 
performed in cases where epilepsy is suspected because, with these exams, some extracranial 
causes of seizures can be easily excluded 6,63. One study said that dogs are more likely to be 
diagnosed with IE when the space of time between the first and second seizure is longer than 
four weeks 16. StE can be diagnosed by a variety of diagnostic imaging tools (e.g. MRI, CT-scan, 
x-rays), CSF examination and post-mortem exam 1. In a new study, there was a higher agreement 
between veterinarians about seizure’s semiology when identifying a primarily generalised seizure 
than a focal seizure 5. On the other hand, there was a low percentage of agreement regarding the 
presence or not of consciousness 5. The level of diagnosis accuracy depends on the veterinarian 
experience and specialists are less likely to misinterpret the signs of epileptic seizures 5.  
 
1.5.1 DISEASES THAT MAY MIMIC EPILEPTIC 
SEIZURES 
 
In the beginning, an epileptic seizure may be easily confused with other pathologies that may 
mimic epileptic seizures (Table 5). Some examples of these conditions are behaviour 
disturbances, cataplexy/narcolepsy, neuromuscular weakness, compulsive disorder, paroxysmal 
dyskinesia, idiopathic head tremor, syncope/heart disease and vestibular disease 7,138,139. To 
clarify whether the dog experienced an epileptic seizure, the veterinarian should undertake an 
exhaustive clinical examination including a neurological examination and collect a thorough 
anamnesis. It is important that the veterinarian can understand whether the events described by 
owners are indeed an epileptic seizure because it will therefore affect the diagnostic approach. It 
is advised that veterinarians have a standard questionnaire prepared for owners to get as much 
information as possible from owners 139. 
A syncope happens as a result of an unexpected decrease of brain blood perfusion which 
manifests in a sudden loss of consciousness, commonly described as collapse 140. The most 
common cause of syncope in dogs is heart disease 102. When differentiating an epileptic seizure 
from a syncope, many details may be essential to exclude one of those events. Generally, a 
syncope is shorter in duration when compared with an epileptic event and dogs can rapidly 
recover after a syncope whereas in an epileptic event, they normally exhibit post-ictal signs such 
as confusion and disorientation 9,102. When a dog experiences a syncope, owners commonly 
describe an exercising event such as running, as well as coughing beforehand 138. The age of the 
dog may also give important information regarding the aetiology of the event. Generally, heart 
disease is diagnosed in older dogs whereas IE is more frequently diagnosed in young dogs 140. 
Some breeds such as Cavalier King Charles Spaniel, Boxer and Doberman Pinscher dogs may 
be predisposed to heart disease 141 and therefore the likelihood of experiencing a syncope is 
increased in these breeds. 
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Paroxysmal dyskinesias (PDs) are movement disorders characterised by sudden and involuntary 
episodes of muscle movements that leads to abnormalities in the normal gait and posture but 
without consciousness impairment 140,142. Normally, it is hard to distinguish from an epileptic 
seizure because the clinical manifestations are similar between each other 40,139. However, it is 
known that some differences exist, which may help establishing the diagnosis. Typically, during 
a PD episode, consciousness is not affected, autonomic signs are absent and there are no 
abnormalities regarding post-ictal behaviour 40,139. Dogs with PDs may be able to return to their 
previous activity since consciousness is not impaired 139. Generally, these changes are not 
frequent in the case of epileptic seizures 40. It is possible to perform some genetical exams in 
some breeds like Cavalier King Charles Spaniel with the purpose of PD’s diagnosis since PD is 
frequently seen in this breed 143. 
Idiopathic head tremor is included in the PDs disorders 142 and it has been mainly identified in 
Doberman Pinscher 144 and English Bulldogs 145 and it is characterised by fast and rhythmic 
myoclonus of the head, that may move vertically or horizontally 144. The aetiology of this disease 
is still unknown and this condition may be easily confused with a focal seizure. However, in cases 
of idiopathic head tremor, the consciousness is not impaired 144,145. A study reported that owners 
were able to stop the episode by simply calling them or asking them to get up 146. 
Narcolepsy is a sleep disorder often underdiagnosed in dogs characterised by excessive 
somnolence and it is normally accompanied by cataplexy, which is defined as a sudden flaccid 
paralysis 50,63. Cataplexy may happen alone and it is normally triggered by emotions (e.g. anxiety, 
anger, excitement) 81. Diagnosing narcolepsy in dogs may be challenging because not only its 
symptoms are difficult to identify but also because owners may see an excessive sleepiness as 
something normal.  
Myasthenia gravis is a neuromuscular junction disorder that may be acquired or congenital 147. 
The acquired form is more commonly observed in dogs and is characterised by an autoimmune 
response against acetylcholine receptors at the neuromuscular plate 147,148. The clinical 
presentation is often confused with a focal seizure since it also leads to muscle weakness and 
abnormalities in the gait and posture 50. Episodes are frequently observed after stimulating-
situations such as exercise and it may worsen while it intensifies 50,147.  
Vestibular syndrome is another disorder that may be confused with epileptic disorder if a thorough 
neurological examination is not performed 149. Even though it is more frequently seen in cats than 
in dogs, vestibular syndrome is mainly characterised by ataxia, which may be further classified in 
cerebellar or peripheral, depending upon its aetiology 149. Generally, some signs of vestibular 
syndrome are distinctive of this disorder such as head tilt, circling and nystagmus 50. Also, 
consciousness is never impaired in case of vestibular syndrome, so these signs may be 
sometimes enough to exclude epileptic disorder 149.  
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Compulsive and behaviour disorders are frequently associated with epileptic disorders but 
sometimes these behaviour disorders may happen singly. For this reason, it is important to 
understand whether these behaviour changes are induced by mechanisms underlying epilepsy 
or if they are provoked by other diseases or environmental factors 140. Factors such as stress, 
genetics, pain or conditioned behaviour may be responsible for behaviour disturbances such as 
tail chasing, foot or hand chewing, excessive licking, aggression, excessive vocalisation, among 
others 140,150. Some of these disturbances may also be seen during the prodrome or in the post-
ictal phase, so it is important to understand whether the other phases of the epileptic episodes 
are present. Also, behaviour changes associated with epilepsy cannot be stopped by the owner 
and dogs will manifest these disturbances regardless the presence of the owner 140.  
Even though some disorders may have identical clinical presentations that could possibly be 
misunderstood as an epileptic episode, there are still some characteristics that may strengthen 
the identification of an epileptic seizure. For instance, generalised seizures may have a distinctive 
clinical presentation. Generally, they are defined as short in time, may occur during resting time 
and usually the post-ictal phase is associated with autonomic signs such as hypersalivation, 
urination or defecation 139. Autonomic signs are generally associated with epileptic seizures 15. 
Also, some behaviour abnormalities are generally evident in the post-ictal phase like 
aggressiveness, disorientation, anxiousness or seeking behaviour 139. Ictus phase is described 
as intense and non-reversible and, while owners may revert other disorders like PD or idiopathic 
head tremor during the event, ictus phase in IE will not cease regardless owners’ efforts 139. 
Another difference regarding epilepsy is the fact that, on the post-ictal phase, animals will not be 
able to return to the activity they were performing previously. This happens because dogs usually 
lose their consciousness 139. 
Focal seizures may be more harder to distinguish between other disorders because sometimes 
consciousness is not impaired or autonomic signs are absent, which may be challenging for the 
veterinarian 139. In this case, the age at the onset as well as the presence of post-ictal signs should 
help to establish a definitive diagnosis 139,142.  
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Table  5: Different aetiologies that may present similar clinical manifestation to IE (Adapted from 
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1.5.2 SIGNALMENT AND CLINICAL EXAMINATION 
 
When receiving a dog at the hospital that might have suffered a seizure, the main question to 
answer is whether that dog experienced indeed an epileptic seizure. Good and clear 
communication between owners and veterinarian plays a key role in helping formulate a list of 
possible differential diagnoses 6. Most of the cases, the veterinarian does not witness the 
seizures, so the clinical classification of seizures must rely on owner’s observation and description 
of the event as well as in video-recordings.  
The veterinarian should ask the owner to describe the episode as accurately as possible, 
including physical manifestation, duration of the episode, frequency, abnormal behaviours 
preceding and succeeding the episode and its severity 17,63. During the appointment, routine 
questions about the patient should be asked as well as more specific questions such as existence 
of clinical history of seizures in other animals genetically related with the patient, possible trauma, 
noteworthy behaviour changes, type of diet, changes in the normal daily routine, if the patient has 
been diagnosed previously with other diseases, treatments that the patient has done or is 
currently doing, possible access to toxins, among other questions 17,63,151.  
Details about the patient such as species, gender, breed and age at the first episode are of great 
value to determine whether possible IE is presented. As previously discussed, some breeds have 
a genetical predisposition for IE, which is mostly diagnosed in young dogs, especially in those 
aged between six months to six years. In some cases, dogs may start exhibiting seizures at an 
earlier stage of their life and under these circumstances, StE related to congenital or genetic 
abnormalities is likely 22. Therefore it is vital to ensure a proper distinction between StE and IE is 
made, especially in small breed dogs that seemed to be more predisposed to structural 
abnormalities 22.  
Also, some breeds are predisposed to certain diseases that may induce seizures as well. For 
example, Boxers have a high incidence of intracranial tumours whereas Maltese dogs are 
predisposed to inflammatory diseases that may affect the brain 63. Hydrocephalus and 
hypoglycaemia are relatively common in toy breeds, so both should be considered as a differential 
diagnosis 151. It is also known that the older the dog, the higher the likelihood of StE. Even though 
that is unlikely to detect abnormalities at the MRI in young dogs, this exam should still be 
performed if possible, to strengthen the diagnosis of IE.  According to De Risio, in dogs that exhibit 
neurological abnormalities, it is important to ask the owner about the onset of the episode to 
distinguish between acute and chronic situations and also about its course to distinguish between 
static, progressive, relapsing or regressive 151.  
A detailed general examination may be helpful to detect underlying abnormalities in vital organs, 
that may be the origin of seizures or may induce similar symptoms that mimic an epileptic seizure. 
This general examination should be performed during the interictal period 51. As stated by 
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DeLahunta et al., focal asymmetrical manifestations may suggest neoplasia, vascular 
compromise, trauma, focal infection or non-infectious meningoencephalitis 51.  
 
1.5.3 NEUROLOGICAL EXAMINATION  
 
A thorough neurological examination may indicate which part of the nervous system is affected 
and therefore it helps to identify the localisation and distribution of the lesion 151. The presence of 
interictal neurological deficits indicates that other causes other than IE are likely, especially if 
these deficits persist for a long period 35,151. However, the absence of abnormalities on the 
neurological examination does not completely exclude StE 6. The presence of irregularities on the 
neurological examination may happen in dogs with IE, although these do not extend for a long 
period of time 150. 
Through neurological examination, it is possible to evaluate the integrity and function of the 
regions that constitute the nervous system. Neurological examination includes evaluation of 
mentation, gait, posture, muscles mass/tonus, spinal nerve reflexes, nociception, proprioception, 
behaviour, cranial nerve function and postural reactions 6,151. Normally, a seizure indicates that 
the forebrain is somehow affected but after recovering from the episode, dogs do not often exhibit 
neurological abnormalities unless noteworthy brain injury has occurred 6,151. Thus, it is expected 
that a dog with IE does not show neurological deficits during preictal stages. According to Dewey 
and Costa, unilateral menace response deficits, hemiparesis, circling, head tilt and unilateral 
decrease of proprioceptive placing may be indicative of StE 50. Patient signalment and physical 
as well as neurological examination would influence the diagnostic approach that will be followed 
later 6. The majority of metabolic diseases that may lead to seizures do not induce neurological 
abnormalities during the interictal period 51. In one study, dogs that presented sporadic single 
seizures were more likely to be diagnosed with IE than dogs that were presented with cluster 
seizures 33. 
 
1.5.4 ELECTROENCEPHALOGRAM  
 
EEG can give an absolute, definitive diagnosis of IE together with clinical manifestations of 
epilepsy and diagnostic exams 139. EGG is especially useful for the diagnosis of IE because it 
allows differentiating epilepsy from other paroxysmal diseases since it evaluates the functionality 
of the brain 53,152. However, EEG is not widely available for veterinarian use mainly because it 
requires extensive knowledge to be used. Conversely is widely used in humans in the diagnosis 
of epilepsy, most of the times together with video-recording 153. In most of the dogs, general 
anaesthesia is required to perform an EEG since any movement may compromise the results, 
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which is another inconvenient for the use of the EEG in veterinary practice 154. Factors like muscle 
contractions, restraint methods, type of electrodes and sophisticated EEG instrumentation may 
difficult the interpretation of results 139. In human medicine, video-EEG is a reliable and useful tool 
for the diagnosis and characterisation of epileptic seizures 5. However, in veterinary medicine 
video-EEG is not currently used because its reliability is not as good as in humans 5.  
 
1.5.5 HEMOGRAM, SERUM CHEMISTRY, URINALYSIS 
AND BILE ACIDS LEVELS  
 
As previously said, the minimal database including hemogram, serum chemistry, urinalysis and 
bile acids levels are a key role in excluding frequent extracranial causes of seizures, most related 
with metabolic disorders 63. The required minimal database may vary among patients, especially 
taking into consideration their age 17. For example, in dogs younger than one year old that were 
not dewormed, the faecal exam could be performed when severe parasitism is suspected 17. 
If the seizures are being provoked by a hypoglycaemia or by electrolytes imbalance such as 
hypocalcaemia or hyponatremia, these can all be easily identified on a serum chemistry 63. 
Hepatic failure is likely in the presence of hyperammonaemia together with increased levels of 
hepatic enzymes 51 and non-regenerative anaemia 63. Increased levels of serum urea, non-
regenerative anaemia and abnormalities on urinalysis such as increased protein-creatinine ratio 
and isosthenuria may also be suggestive of renal disease 51. Abnormalities on normal values of 
pre and post-prandial bile acids and triglycerides may also suggest the existence of a 
portosystemic shunt or hepatic failure, especially when together with another anomaly such as 
increased hepatic enzymes and hyperammonaemia 63. The presence of increased levels of white 
blood cells (WBC), especially neutrophils, are indicative of inflammatory/infectious processes in 




Regarding the clinical history of the patient, a video-documentation should be asked to owners to 
analyse certain characteristics such as frequency, duration and event patterns that can strongly 
suggest a diagnosis of epilepsy 18. Video-records have been considered as an essential, 
inexpensive and useful tool for the clinician as it can help to identify the seizure type 5. Video 
recordings are especially helpful when it comes to distinguish between a primary generalised 
seizure from a secondarily generalised seizure that was preceded by a primarily focal seizure 5. 
However, video recordings should not be the unique source to characterise the seizure type. 
Sometimes owners do not record videos from the beginning of the episode and focal seizure can 
1. LITERATURE REVIEW 
34 
 
be missed because its signs are not as visible as in a generalised seizure. Therefore this can lead 
to a misconception of the seizure type 5,110.  
 
1.5.7 IMAGING AND CSF ANALYSIS  
 
Advanced imaging such as MRI or CT-scan are often used to help the veterinarian identify 
intracranial causes of seizures. The introduction of MRI and CT-scan for diagnostic purposes has 
allowed the detection of structural and morphologic brain anomalies that may be the cause for 
epileptic episodes 155. According to the IVETF, these exams are important for ruling-out StE and 
in cases of resistance to AEDs 139.  
In one study, 26% of  dogs that experienced an epileptic episode before the age of one year were 
posteriorly diagnosed with a structural brain disease that could only be identified by the MRI 130. 
These same dogs had normal neurological exams, which highlights the importance of these 
advanced imaging exams on the diagnosis.  
Preferably, any dog with recurring seizures should undergo an MRI and a CFS analysis to exclude 
possible StE 63. CSF analysis is way more important in the absence of remarkable brain anomalies 
and when inflammatory/infectious diseases such as meningoencephalitis are strongly suspected 
63. However, CFS analysis is not indicated when increased ICP is suspected 51. Tumours and 
encephalitis were described as the most common detected causes of StE 35. Even though MRI is 
performed with the aim of detecting causes of StE, it is possible to detect abnormalities secondary 
to epileptic events. In a study, abnormalities caused by seizures were observed as hyperintense 
zones on T2-weighted images in brain regions that are normally affected by over-concentration 
of excitatory events 156. The fact that these lesions were presented after seizures events and 
without any inflammatory or infectious process highlighted this hypothesis 156. As said by Smith 
et al., a low percentage of abnormalities (2.2%) was found during the MRI in dogs younger than 
six years with recurrent seizures but with an unremarkable neurological examination 34.  
Although MRI and CFS are crucial to exclude many causes of StE, these exams are costly and 
may not be performed if owners cannot bear the financial cost 6. The recommendations by the 
IVETF is to perform an MRI in the presence of the following circumstances: first episode occurring 
before six months of age or after six years old; interictal abnormalities detected during the 
neurologic examination; presence of SE or cluster seizures and when resistance to AEDs is 
suspected 139. 
Similarly, abdominal ultrasonography and radiographs may be helpful in excluding causes of StE, 
with the advantage of being reasonably inexpensive exams. Abdominal radiographs may show 
possible abnormalities like metastasis, primary tumoral masses or evidence 
microhepatica/hepatomegaly 17. On the other hand, three-view thoracic radiographs (right and left 
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lateral and ventrodorsally) may also show metastatic processes, primary tumoral masses and 
microcardia/cardiomegaly 17. Abdominal ultrasonography is particularly useful to diagnose 
portosystemic shunts or supporting the diagnosis of renal failure, that are both common anomalies 
that may induce seizures. Rectal scintigraphy may also be suitable for the diagnosis of the 
portosystemic shunt 51. A summary of possible diagnostical approach for IE can be seen on Figure 
3. 
 
Figure 3: Diagnostic approach to idiopathic epilepsy (Adapted from Vernau 2015). 
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1.5.8 TIER-SYSTEM  
 
The IVETF defined a three-tier system of confidence criteria regarding the diagnosis of IE (Table 
6). This system may assist the veterinarian in identifying the appropriate diagnostic exams as well 
as improving the accuracy of diagnosis.  
The tier I confidence level is the minimal requirements that should be assured to properly 
diagnose IE. In what concerns to the diagnostic exams, to be classified as a tier I, minimal 
database is required. According to De Risio et al., the minimal database requirements include a 
hemogram, complete serum chemistry (e.g. electrolytes analysis, hepatic enzymes, urea, 
creatinine, total protein, albumin, glucose, cholesterol, triglycerides, ammonia and fasting bile 
acids) and urinalysis 139. If the patient has a family history of IE, this finding may support the 
diagnosis 139.  
The tier II confidence level adds all the diagnostic exams that should be performed for a tier I 
confidence level in addition to a brain MRI and CSF analysis.  
The tier III confidence level is considered when tier I and II requirements are achieved, without no 
remarkable abnormalities and in the addition of an EEG 139. When abnormalities are detected on 
these exams, a diagnosis of StE is likely. In order to accurately diagnose IE, a tier II confidence 
level should be achieved, however some owners may not be able to afford some diagnostic exams 
such as an MRI, so in these cases a tier I confidence level should be attained. CT-scan may be 
considered over an MRI since it is normally cheaper. The EEG is widely used for scientific rather 
than medical purposes, so in most cases, a tier III confidence cannot be achieved in a normal 
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Table  6: Tier system of confidence for diagnosis of IE (Adapted from De Risio et al. 2015). 
TIER SYSTEM OF CONFIDENCE 
CRITERIA FOR A DIAGNOSIS OF IE 
DIAGNOSTIC COMPLEMENTARY EXAMS 
TIER I 
History of two or more unprovoked epileptic seizures 
separated by at least 24 hours 
Dog aged between six months and six years 
Unremarkable interictal physical and neurologic examination 
Normal hemogram, serum chemistry and urinalysis 
TIER II 
Tier I factors 





Tier II factors 





In human medicine, the main objective of the treatment is to achieve total remission of seizures 
in the patients and provide a higher QoL with minimisation of side effects related with AEDs 49. 
However, in veterinary medicine, achieving a total remission of seizures is unlikely due to AEDs 
resistance, that is evident when compared with human medicine 49. According to Potschka et al., 
less than 50% of dogs that had been treated for IE achieved remission 157. Veterinary medicine 
continues to work towards trying to decrease seizure frequency, severity and duration as well as 
decreasing the adverse effects associated with AEDs 4,139.  There is no cure for epilepsy and 
spontaneous remission is rare. Thus a lifelong treatment based in AEDs that provide suppression 
of epileptic seizures needs to be implemented in most cases 158. Therefore, it is crucial to ensure 
that safety regarding AEDs is accomplished. 
There are more AEDs available in human medicine than in veterinary medicine, mostly because 
some AEDs are rapidly metabolised and excreted in dogs, hence the importance of using drugs 
with a long half-life time in this species 159. 
In contrast to what happens in human medicine, epileptic seizures are not classified into different 
presentations in veterinary medicine, so AEDs are used regardless of seizure’s type 15. Typically, 
the use of a single drug on treatment is considered enough for proper management of seizures 
49. Nevertheless, some dogs may need combined therapy when a satisfactory response to the 
first-line drug is not achieved 49. 
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Some studies claim that around 30% of the dogs diagnosed with IE are refractory to the treatment, 
showing resistance to the most commonly used AEDs such as PB and potassium bromide (KBr), 
thereby making it harder for veterinarians to find a suitable, efficient treatment for some dogs 
157,160,161. AEDs only suppress seizures and do not act against epileptogenesis, so they do not 
prevent the development of the disease, which highlights the importance of developing more 
efficient and tolerable drugs 159,162. Also, tolerance and resistance to the AEDs are particularly 
common and even dogs that have achieved remission can again experience seizures, despite a 
good therapy and management from both veterinarian and owner 163. According to Hülsmeyer et 
al., 71% of dogs were found to have resistance to AEDs and recurrent cessation of medication 
was related to therapeutic failure  30.  
Dogs that had experienced a more significant number of seizures before treatment are more 
susceptible to develop tolerance against AEDs 164. These problems are generally resolved by 
simply increasing the dosage of the chosen drug, especially when seizures suddenly occur after 
reaching to a steady-state 163.  
The veterinarian should consider factors related with the AEDs such as their availability, 
effectiveness, tolerability and side effects, ensuring owners are aware of possible complications 
with the treatment. Also, the factors related with the patient such as its general health and factors 
related with the owner such as its financial status and cooperation should also be considered 
before starting the treatment 132,165,166. According to the IVETF, a treatment should be 
administered when in the presence of the following conditions: interictal period shorter than six 
months (e.g. when two or more epileptic seizures occur within a six-month period); when in 
presence of SE or cluster seizures; when the post-ictal signs are severe or last for more than 24 
hours or when the epileptic seizure frequency and/or duration increases 165,166. Before initiating 
the treatment, it is essential to certify the absence of underlying diseases that may originate 
seizures as well. Most of the times, owners overreact to the diagnosis of epilepsy because 
epilepsy is typically seen as a severe disorder. Veterinarians play a key-role to ensure that 
unnecessary euthanasia is not performed when dealing with such cases 132. Also, veterinarians 
should explain to owners that epilepsy might be a life-threatening condition when in the absence 
of treatment but that seizures can be controlled with a suitable and appropriate treatment. 
Furthermore, owners should be aware that treatment may not be entirely successful, despite the 
efforts from both parties 132. The sooner the treatment starts, the more effective it is likely to be 
132,165. Male dogs are likely to have an AEDs resistance compared with female dogs, leading to a 
poorer prognosis 167. A study reported that AEDs might affect canine cognition and, therefore, it 
could weaken their performance on routine actions such as learning tricks or complete tasks 168. 
Without appropriate treatment, frequency of seizures may increase as time passes, thereby 
worsening the symptoms and leading to a poorer prognosis. The honeymoon effect is used to 
mention the tolerance against some AEDs during a chronic treatment, which may vary among 
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dogs, with some of those developing resistance to specific AEDs while others do not 165. This 
effect is commonly seen in dogs with refractory epilepsy, when a chronic treatment with AEDs 




PB is a barbiturate derivate and is commonly used in the treatment of IE in dogs, with a reported 
effectiveness of 60% to 80% in controlling seizures 49,170. Monotherapy with PB is commonly used 
in both human and veterinary medicine, despite its side effects 49,171. Many formulations are 
available for use. However, oral formulations are undoubtedly the most used. When PB is orally 
given, the peak serum concentration is achieved 4 to 8 hours after administration 172,173. IE is a 
chronic disease, requiring continuous treatment to ensure seizures cessation, thus oral 
administration is the simplest way to owners provide medication to their pets. As PB is mainly 
metabolized in the liver, it intensifies the activity of cytochrome P450, a potent enzyme that leads 
to the production of reactive oxygen species that are potentially damaging to the liver, thus the 
importance of regular monitorisation of PB serum concentration and hepatic enzymes 170,174. The 
median half-life known for PB is 88.7 to 99.6 hours 173. As PB may be potentially hepatotoxic, its 
administration should be avoided in dogs with pre-existing or suspected hepatic disease. PB 
should not be used in combination with other drugs that are metabolised by cytochrome P450 
because it may decrease those drugs concentrations,  therefore decreasing their efficacy 175. 
Similarly, PB should be avoided in combination with drugs that inhibits cytochrome P450’s activity 
as it may lead to toxicity 176.  
When choosing the best treatment, PB is the first option for individual therapy and KBr remains 
an add-on drug because PB provides lower seizure recurrence when compared with KBr 176. 
Nonetheless, a study suggests that KBr may be a reasonable choice as a first-choice AEDs, even 
though seizure freedom is not as effective when compared with the use of PB 176. Like all drugs, 
some side effects may be seen like polyuria, lethargy and ataxia 170,176,177. These side effects 
usually are dose-dependent and the higher the dosage, the higher the likelihood of developing 
side effects 178. PB is associated with an increase of hepatic enzymes such as serum alkaline 
phosphatase (ALP), serum alanine transaminase (ALT) and ϒ-glutamyl transferase (GGT) 179. 
The reason for such is related to enzyme induction by PB’s metabolization in the liver 179. Even 
though PB provokes some side effects during long-term treatment, this drug is relatively safe and 
moderately reduces the frequency of the seizures 172,173. A scheme regarding the management of 
PB treatment is observed in Figure 4. 
According to Bhatti et al., the recommended starting oral dosage should be 2.5 to 3 mg/kg twice 
a day, however, it may need to be adapted according to seizure’s control, side effects and serum 
concentrations 165. After initiating the treatment, PB serum concentration should be monitored 
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every 2 weeks until an acceptable serum value is achieved, which is known to be between 25-30 
mg/L in dogs 165. This range of values has been identified as the optimal concentrations regarding 
seizure control and minimal side effects 165. Hemogram and serum chemistry exams are 
recommended every six months after initiating treatment to detect abnormalities that may be 
induced by chronic use or high dosage of AEDs 165,170. Before starting combined drug therapy, 
PB dosage can be increased if seizure frequency does not reduce after initiating treatment, 
however, PB serum concentrations should not overcome 35 mg/L due to a higher likelihood of 
hepatic damage 165,176. Monotherapy with PB should be stopped if the dog starts developing 
adverse effects or an add-drug should be implemented if PB serum concentrations are constantly 
above 30mg/L 165,170,176. Revaluations and optimal timing for blood collecting for PB serum 
measurement, hemogram and serum chemistry may vary among studies.  
 
 
One study reported an acute PB intoxication where the affected dog developed severe 
haematological abnormalities such as leukopenia, thrombocytopenia and anaemia 180. As the 
main objective of treatment is to achieve a partial or total remission of seizures, the dosage of PB 
Figure 4: Treatment approach using phenobarbital as monotherapy (Adapted from Bhatti et al. 
2015) 
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should not be changed if seizures are controlled even if PB serum concentrations are below the 
optimal amount 165. PB serum concentrations should remain at the lowest possible concentration 
that is effective in controlling seizures and their frequency, whilst minimising the possible side 
effects 181. Every time that remission is achieved, routine exams may be performed every 12 
months 165. Treatment with PB is often associated with functional resistance and tolerance, hence 
leading to a failure in controlling seizures 182. 
 
1.6.2 POTASSIUM BROMIDE 
 
Nowadays, there are more AEDs available for the management of IE. KBr is still one of the best 
options since it is inexpensive, relatively safe, well-tolerated when chronically used and efficient 
177,183. A combination of KBr with PB is the most commonly combined therapy used when PB per 
se does not provide seizure freedom and the synergetic effect between both drugs allows a better 
control of seizures, leading to at least 50% reduction of seizures 44,49,184. When compared with 
PB, KBr is not as effective as PB in controlling seizures 170,176. A monotherapy with KBr was 
already reported in a study 176 although its single-use in treatment of IE in dogs has not been 
approved in the majority of the European Union (EU) countries 165. Nevertheless, it is approved 
as an add-on drug in combination with either PB or imepitoin 165,176,177.  
KBr is available in oral formulations that allow an easier way of administration. When compared 
with PB, KBr has a slower metabolization after oral administration, with a median half-life of 46 
days 185, but other studies suggest different values between 24 to 46 days 170,183,185. KBr is 
completely excreted in the urine, thus it is not hepatotoxic and it may be administrated in animals 
with hepatic abnormalities 165,166,170. However, precautions should be taken when giving KBr to 
dogs with renal disease as the excretion is compromised and this may lead to toxicity 186. 
Moreover, some side effects have been associated with KBr such as polyphagia, 
polydipsia/polyuria (PD/PU) and sedation 170,177. The measurement of KBr serum concentration 
should be performed three months after introducing this drug, taking months until steady-state 
values are achieved 165,170. An interval range of 1000 – 2000 mg/L is desirable when undergoing 
a combined therapy with PB 165,170,185. KBr serum concentration should be measured three and 
six months after initiating the treatment but it can also be performed every 12 months if remission 
is attained 165,170. 
During a combined treatment with PB, KBr should be given orally, twice a day, in a dosage of 15 
mg/kg and should be given alongside food, avoiding gastrointestinal disturbances like vomiting or 
diarrhoea 165,187. It is recommended that the administration of a loading dose is given to allow for 
a steady-state concentration to be achieved at an earlier stage, resulting in better control of 
seizures 170. According to the IVEFT, a loading dose of 125 mg/kg/day divided in three to four 
times a day, during five consecutive days is advised and owners must be aware of possible side 
1. LITERATURE REVIEW 
42 
 
effects that may occur such as gastrointestinal signs or sedation 165,170. As previously stated for 
PB, routine exams should be performed such as hemogram and serum chemistry before initiating 
treatment with KBr and every six months afterwards 165. In specific situations when seizures are 
frequent even when undergoing treatment with PB or when side effects may be life-threatening, 
a loading dosage of KBr may be administered to control seizures or to discontinue the treatment 
with PB, respectively 165. This loading dosage will allow for a faster increase of KBr serum 
concentration, resulting in a quicker response 170. During a combined treatment with PB and KBr, 
it may be necessary to readjust KBr dosages, depending upon seizures frequency and side 
effects presented.  
 
1.6.3 IMEPITOIN  
 
A new drug that has been approved by EU for the treatment of IE in dogs is imepitoin, a low-
affinity partial agonist of GABA receptors drug that was initially developed for humans 165,166. 
Imepitoin seems to be well-tolerated and efficient in both dogs and humans, however, its use was 
discontinued in humans due to variability in pharmacokinetic properties 188. Its effectiveness and 
fewer side effects make it a safe and reliable option for treatment 166,177,188. Imepitoin is not 
normally chosen as a first-drug line in the treatment of IE but it is frequently used as add-on drug 
when other standard AEDs fail in controlling seizures or when side effects provoked by those 
AEDs are life-threatening, so dosage of the main AED has to be reduced 177. However, a study 
suggested the use of imepitoin on monotherapy that was proven to be more efficient than in 
combined therapy with other AEDs 171. 
Moreover, a study found that imepitoin is more stable and shows better results in controlling 
seizures when compared with KBr as an add-on drug 159. Infrequently, imepitoin may be used as 
a first-line drug and a study demonstrated that either PB or KBr could be used as add-on therapy 
in cases where dogs are refractory to the treatment with a maximum dosage of imepitoin 177. 
According to the IVETF, imepitoin is mainly used in cases of recurrent generalised seizures 165. 
Some side effects associated with imepitoin may include sedation, PD/PU and polyphagia  
158,188,189. However, these side effects are uncommon which makes it an advantage when 
compared with other AEDs  158,188,189. In one study, hyperactivity appeared to be the most common 
side-effect associated with imepitoin when compared with other AEDs 188. 
In contrast to what frequently happens with other AEDs, dogs that had been treated with imepitoin 
did not present behaviour changes during treatment and therefore owners may prefer this course 
of treatment 159. As imepitoin has an anxiolytic effect, it is possible that behaviour abnormalities 
such as anxiety or aggression, which are commonly described in epileptic dogs, are well-
controlled 158,159. Some studies have not discovered significant alterations in both hemogram, 
serum chemistry and urinalysis, which suggests that imepitoin does not influence metabolic 
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pathways regarding vital organs such as liver or kidneys 158,159,188. Imepitoin is mainly metabolised 
by the liver and its excretion mostly happens through the faeces but no noteworthy alterations 
have been detected in the liver that could be induced by the metabolization of this drug 158,165. 
There is no satisfactory evidence on safety regarding the use of imepitoin in dogs with 
concomitants diseases such as heart or gastrointestinal disease, despite undetectable 
abnormalities in vital organs 165. Therefore, the use of imepitoin in such cases should be avoided.  
According to the European Medicines Agency (EMA), the initial recommended dosage of 
imepitoin is 10 mg/kg, twice a day, that could be increased up to 30 mg/kg if necessary 190. In a 
study by Rundfeldt et al., a dosage of 30 mg/kg, given orally twice a day, resulted in an active 
stabilisation of seizures in dogs that were suffering from generalised tonic-clonic seizures 188. 
Another study claimed that imepitoin at a dosage range of 5 to 30 mg/kg was sufficiently efficient 
in decreasing the frequency of seizures and was more tolerated than other AEDs 159. This 
therapeutic range was found to be safe in other studies and the therapeutic range where side 
effects are non-existent or tolerable was found to be between 1 mg/kg to 30 mg/kg 189,191. 
However, higher doses have shown to be more efficient in controlling seizures when compared 
with lower dosages but may be sensible to initiate therapy with lower dosages as higher dosages 
may increase the risk of developing undesirable side effects 188. The same study suggested that 
imepitoin may be used in chronic therapy because it is unlikely that antiepileptic properties are 
lost throughout the treatment 188. 
It is considered unlikely that tolerance against imepitoin develops during a prolonged treatment, 
which enables its use on chronic treatments for IE 159,191. The daily dosage of imepitoin can be 
moderately increased up to 30 mg/kg in cases where there is an unsatisfactory control of seizures 
165. In contrary to what happens with PB and KBr, serum concentrations of imepitoin are not 
routinely controlled because an ideal range of serum drug concentration have not yet been 
defined 165. Equally to what happens with other AEDs, routine blood analysis should be performed 
every six months after initiating treatment with the selected drug, with the objective of early 
detection of side effects 165. According to Rundfeldt et al., the median half-life time was found to 
be two hours 159. Even though there is no evidence of pharmacological interactions between 
imepitoin and other drugs, especially other AEDs, precaution should be taken if DZP is added to 
a dog that is submitting a treatment with imepitoin because both drugs are GABA receptors 
agonists, therefore undesirable interactions may happen 158. 
 
1.6.4 LEVETIRACETAM  
 
Levetiracetam is one of the licensed UE drugs for the treatment of IE and its use as an add-on 
drug has been recommended in some studies 166,171. According to Volk et al., 57% of epileptic 
dogs that were resistant to first-line AEDs positively responded when levetiracetam was added to 
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the treatment 169. Some studies claimed that levetiracetam represents a safe, well-tolerated drug 
and side effects are practically non-existent but sedation and ataxia had been described as the 
most common adverse effects 164,192. The kidneys quickly metabolise levetiracetam and its half-
life time varies between four to eight hours 165,193. Because its metabolization mainly occurs via 
the kidneys, it should be avoided in dogs with renal disease as the clearance of this drug may be 
affected and could possibly lead to toxicity 194.  
On the other hand, levetiracetam may be a good choice for dogs with hepatic disturbances as 
hepatic metabolization is minimal 194. Levetiracetam does not stimulate hepatic enzymes’ activity, 
therefore tolerance is less likely to occur in contrast to what happens with AEDs such as PB 163. 
According to Patterson et al., the recommended dose of levetiracetam given orally is 20 mg/kg 
twice or four times a day due to its short half-life time and it can be given parenterally to dogs 
without complications 193. However, the dosage range is 5 to 30 mg/kg, twice or three times a day 
195, so dosage may be adjusted to every situation. A study reported that levetiracetam was 
associated with tolerance in the long-term, frequently called the honeymoon effect, which may be 
a disadvantage in a chronic treatment 169. Similarly to what happens with imepitoin, the ideal range 
of serum concentration is not yet known for levetiracetam 192. According to Moore et al., it may be 
necessary to increase the dosage of levetiracetam when in a combined therapy with PB since PB 
seemed to slightly change the normal pharmacokinetics of levetiracetam 196. This finding may 
suggest that the actual recommended dosage possibly is not sufficient to maintain a therapeutic 




BZDs are a class of drugs that may be used in the treatment of IE, although its efficiency is poorer 
when compared with other drugs and BZDs are associated with a high risk of developing 
resistance and tolerability, thus reducing their efficacy 159. Nevertheless, these drugs, especially 
DZP, are primarily chosen for treatment of SE and not for prolonged treatments 163,172. Since DZP 
is easily absorbed through the BBB, its therapeutic concentration within CNS is rapidly achieved, 
which makes it a useful choice for the treatment of SE 172. 
 
1.6.6 NON-LICENSED EU DRUGS SUGGESTED FOR USE 
IN THE TREATMENT OF IE IN DOGS 
 
Other drugs have been suggested for the treatment of IE in dogs, however, there still is limited 
clinical and scientific evidence that could support the utilisation of these same drugs. These drugs 
are used in human medicine and some examples are zonisamide, felbamate, topiramate, 
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gabapentin and pregabalin 165. Even though many studies have been conducted with the aim to 
clarify whether these drugs could be used in the treatment of IE in dogs, none of these studies 
could totally support their efficacy and safety 197–203. Among these drugs, zonisamide is the only 
one that has been approved for the treatment of IE in dogs but it is only licensed in Japan 165. 
According to the IVETF, zonisamide was approved as an add-on drug in cases where therapy 
with PB alone or together with KBr induces undesirable side effects 165,201,203. This drug has the 
potential to decrease the PB dosage, therefore reducing some of its side effects 201. There are 
fewer side effects associated with zonisamide. However, an increase of hepatic enzymes, apathy 
or ataxia may occur 201. Zonisamide is known to have a half-life of 15 hours 50. One disadvantage 
associated with the use of this drug is its high cost when compared with other drugs, which in 
chronic treatments may be a deciding factor given the owner’s financial circumstances 201. 
Zonisamide can be given orally every 12 hours, maintaining a good serum concentration between 
administrations 203. 
 
 ALTERNATIVE TREATMENTS  
In humans, the ketogenic diet (KD) is one of the alternative treatments available to help control 
seizures. This diet is characterised for having an elevated percentage of fats (75-90%), decreased 
percentage in carbohydrates (5%) and moderate in proteins (10-20%) 204,205. This diet exhibits 
anti-inflammatory properties that may help control seizures, mainly when inflammation is 
associated 204. Thus, these anti-inflammatory properties decrease the interleukin (IL) 1B 
expression, which decreases inflammation response and therefore contributes to seizure control 
204. A low carbohydrates diet can be useful in the management of seizures and a study describe 
this diet as an alternative treatment to the medication that can have some unwanted side effects 
206. In one study, dogs fed with KD experienced a reduction of their seizure frequency when 
compared with dogs that were fed with regular commercial diets 207,208. Also, the addition of KD 
as an add-on to PB treatment, in cases of recurrence, helped reduce seizures by 85% 209. 
 
 PROGNOSIS 
The personal opinion of owners concerning their pet’s QoL may influence the decision of 
euthanasia or not 25,210. Owners are likely to choose euthanasia if there is a decrease in their pet’s 
QoL 25,210. QoL is one of the factors that may be crucial to the management of the disease, so 
cooperation from owners is crucial. Many owners may find it difficult to cope with the fact that their 
pets have an incurable disease that requires life-long treatment  25,210. Some owners may not 
have financial conditions to ensure that adequate treatment is provided to their pets 210. Thus, the 
1. LITERATURE REVIEW 
46 
 
prognosis relies not only on the treatment success but also on owner’s cooperation, economic 
status and veterinary expertise 25.  
Some factors that influence the prognosis may include age at first seizure, frequency, treatment 
failure and the presence of SE or cluster seizures 30,128. The prognosis is closely related to the 
number and frequency of seizures. The higher the number and frequency of seizures, the worse 
the prognosis 11. According to Heske et al., age is also a risk factor that influenced the survival-
time and patients that had been belatedly diagnosed with IE had a shorter survival time following 
the diagnosis when compared with those whose epilepsy was diagnosed earlier 18. As stated by 
Lengweiler et al., most of the dogs responded well to the treatment if treated in the early stages 
211. The owner’s economic status is another factor that may affect the prognosis of IE 20. The 
management of IE from the diagnosis to the treatment can be very expensive and some owners 
may not be able to afford such expenses, which may influence the outcome if the protocol for 
diagnosis and treatment of IE is not followed.  
In one study, dogs that had experienced cluster seizures were more likely to be resistant to AEDs, 
which worsens the prognosis in such cases 167. According to Kwan et al., a strong and positive 
response to the first AEDs administered, with proper management of seizures, may be an 
indicator of satisfactory prognosis 212. Most of the euthanasia performed in epileptic dogs are 
related not only with treatment failure but also with the decrease of dog’s health provoked by 
chronic treatment with AEDs 25. SE is also a prognosis factor depending upon its manifestation, 
duration and aetiology 126. According to Sanders, the prognosis is poorer in the following 
situations: dogs that experience a SE that last longer than six hours 129, dogs that have another 
episode of SE less than six hours after the first and dogs that have StE, especially tumours and 
inflammatory processes due to trauma or infection 126.  
Dogs diagnosed with epilepsy may have a shorter life span when compared with healthy dogs. 
One study reported seven years as the median age for dogs with epilepsy 25. Alternatively, Heske 
et al., reported 1.5 years of median survival time following the diagnosis of epilepsy 18. This study 
said that dogs kept as pets presented a higher median survival time when compared with dogs 
that were kept for other purposes such as hunting 18. This finding was probably because owners 
might feel more emotionally connected with their companion pets than with pets that are kept for 
working/hobbies purposes.  
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 HEMOGRAM  
The hemogram is a diagnostic exam that evaluates, quantitatively and qualitatively, the main cells 
that constitute the blood: red blood cells (RBC), WBC and platelets (PLT). The evaluation of these 
parameters should not be interpreted alone but together with other diagnostic tests and physical 
examination. Through hemogram it is possible to evaluate the RBC, the WBC count, the 
haemoglobin (HGB), the haematocrit (HCT), red cells indices such as mean corpuscular volume 
(MCV), mean corpuscular haemoglobin (MCH) mean corpuscular haemoglobin concentration 
(MCHC) and red cell distribution width (RDW), PLT and PLT indices such as mean platelet volume 
(MPV) platelet distribution width (PDW) and plateletcrit (PCT). 
Each of these parameters has different reference values that may vary between blood analysers 
and species 213 . Other factors like age, diet and environment may influence these values between 
patients 213, thus the importance of having reference values for blood parameters. All these cells 
originate from the haemopoietic cells, that are produced in the bone marrow 214. Within the bone 
marrow there are two different types of cell lines: myeloid line and lymphoid line 215. The myeloid 
line consists of granulocytes cells (neutrophils, basophils and eosinophils), monocytes, 
macrophages, erythrocytes, megakaryocytes and mastocytes 215. The lymphoid line consists of 
lymphocytes B, T and natural killer cells (NK cells) 215.  
The hemogram gives information about primary diseases that directly affect the bone marrow but 
also expresses haematological abnormalities resulting from other processes such as infection, 
inflammation, toxicity or neoplasia 216. As hemogram parameters are affected by these factors, it 
is expected that some of these parameters may work as possible biomarkers for some diseases. 
 
 HEMOGRAM PARAMETERS, INFLAMMATION 
AND SEIZURES 
Red cell distribution width (RDW) refers to the size disparity of erythrocytes. A human study 
suggests there might be a correlation between the RDW and inflammation since this parameter 
was increased in many cases of inflammatory diseases such as systemic lupus erythematosus 
or Crohn’s disease 217. As said by Gurler and Aktas, the correlation between the RDW and 
inflammation might be due to the fact that, during inflammation, inflammatory cytokines are 
released within the blood circulation, therefore causing changes in erythropoiesis in bone marrow 
217. Consequently, it results in RBC of different dimensions 217. 
Also, during inflammation, PLT become activated and there is a tendency for  these activated PLT 
to be larger than non-activated PLT, hence an increased MPV 217.  
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During inflammation, WBC are activated and recruited from the bone marrow and circulation to 
the damaged foci 218. The Neutrophils-Lymphocytes Ratio (NLR) may also be an indicator of 
inflammation because it is associated with oxidative stress and cytokines production 218. In one 
study in humans, more than one third of patients with generalised seizures had a significant 
increase of WBC following seizures and a relationship between duration and elevation of WBC 
was detected, so the longer the seizure, the higher the WBC 219. In addition, the elevation of WBC 
was temporary and strictly related to the seizure 219. Another study in humans also found a 
temporary increase of lymphocytes and neutrophils in epileptic patients following a seizure, which 
persisted for 24 hours 220. According to Sarkis et al., a higher WBC and monocyte count was 
found in patients with generalised seizures compared to those with focal seizures 221.  
Finally, another study in humans that evaluated the relationship between EEG and hemogram 
found an increase of WBC and neutrophils in patients that shown abnormalities in the EEG 222. 
This finding emphasises that seizures may alternate the hemogram parameters by inducing an 
inflammatory cascade following the epileptic event. 
 
 NEUROINFLAMMATION 
The neuronal environment is known for being a unique and privileged for having its own immune 
mechanisms, distinct from the rest of the body 223. According to Platt, the neuronal environment 
can be considered as immune-privileged due to the existence of a BBB, absence of a 
conventional lymphatic systemic and limited transferring of peripheral immune cells from the blood 
to the brain 223. Neuroinflammation may be defined as an inflammatory process within the CNS 
224. Many different cells are involved in the neuronal immune response such as microglia, 
astrocytes, neurons, endothelial cells presented in the BBB and peripheral immune cells that 
cross the BBB  223,225,226. All these cells have the capacity of producing and releasing inflammatory 
mediators as well as upregulating their respective receptors 223,225,226. Any damage inflicted 
directly or indirectly to the brain induces acute inflammation, which may evolve to chronic 
inflammation when these mechanisms become exacerbated and prolonged 2. During chronic 
neuroinflammation there is an exacerbated release of cytokines and other inflammatory mediators 
that may cause neuronal injury and consequently neuronal death 2.  
The fact that seizures may trigger inflammation and recurrent seizures may lead to an underlying 
state of chronic inflammation evidence a firm relationship between these processes. In fact, one 
study suggested that inflammation can lead to epilepsy and vice versa, so both may be intimately 
related 223. As inflammation is a physiological mechanism to ensure protection against threatening 
situations, it is not surprising that inflammation is triggered after a seizure episode. For many 
years the relationship between epilepsy and neuroinflammation has been widely discussed by 
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many neuroscientists around the world. The fact that inflammation may trigger seizures and vice 
versa 2, prompted neuroscientists to carry out several studies with the aim to understand the 
pathophysiology behind it 74,100,227–229. A study in humans found a relationship between 
neuroinflammation and some neurological diseases such as Alzheimer disease and multiple 
sclerosis 230. 
In the brain, the inflammatory response is initiated by resident cells of CNS known as glial cells 
229. These glial cells are involved in neuronal modulation of injured neurons, production of myelin, 
buffering of electrolytes/neurotransmitters and play an essential role in modulating the immune 
response in the brain 229,231. Within the glial cells, astrocytes and microglia are key role to 
neuroinflammation 229,232,233. Microglia cells are mainly responsible for innate immunity in the 
brain, but astrocytes and neurons are involved as well 233. According to DiSabato et al., microglial 
cells are presented in both grey and white matter of the CNS, representing at least 10% of the 
total CNS cell population 229. Microglial cells are typically activated when a noxious stimulus like 
infection, inflammation and trauma occurs 234, releasing inflammatory mediators such as 
cytokines or chemokines 229,232. Cytokines such as ILs, tumour necrosis factors (TNFs) and 
transforming growth factor (TGF) are some inflammation mediators released by glial cells, 
following epileptic episodes  2,235. IL-1β, IL-6 and TNF-α are known for being the most important 
inflammatory mediators 236,237. As stated by Platt, there are many mechanisms of regulation for 
cytokines, that include gene transcription, cleavage of their precursors by proteolytic enzymes, 
cellular release and through receptors  223. Microglial cells have phagocytic capacity and are able 
to phagocyte apoptotic neuronal cells to ensure the normal proliferation of neurons and remove 
toxins deleterious to the brain 236,238. However, the perpetuation of microglial activity may lead to 
dysregulation of their normal function. When overstimulated, they have the potential to release 
reactive oxygen species, nitric oxide and inflammatory mediators that, when overconcentrated, 
may be neurotoxic 234,239,240.  
Astrocytes are CNS cells that allow a connection between neuronal and glial cells and regulate 
the synaptic transmission by releasing chemical transmitters 241 that were involved in the 
activation, differentiation and morphology of microglial cells 239. Accordingly, astrocytes produce 
neurotrophic factors that regulate the activity of microglial cells, providing nutrition and protection 
242. When activated by a noxious stimulus, astrocytes become activated and move to the damaged 
foci. Consequently, astrocytes induce the release of cytokines and chemokines that are 
responsible for the activation and recruitment of microglial cells 243. Astrocytes also have the 
capacity of producing nitric oxide and reactive oxygen species that are harmful for the normal 
neuronal regeneration after injury, therefore contributing to the neuroinflammation 244.  
Neuroinflammation may also lead to the recruitment of peripheral inflammatory cells 245. 
Chemokines work as chemo-attractants for peripheral leucocytes 232,246, that move throughout a 
damaged BBB. Chemokines have an important role in regulating microglial cells as well as 
1. LITERATURE REVIEW 
50 
 
promoting different mechanisms such as angiogenesis and neurogenesis 247,248. The BBB is a 
structure composed mainly by endothelial cells and it is first-line protection of the brain against 
injury and pathogens 231. These components regulate whether some blood elements can move 
from blood circulation into vessels and capillaries that are directly related to the brain 231. BBB 
can breakdown during inflammation, changing its permeability and allowing pathogens to cross 
the BBB and reach the brain 229. This increase in permeability is mainly due to the action of 
cytokines and consequently it allows proteins like albumin and other cells like leucocytes to 
circulate from the peripheral blood to the neuronal blood circulation 229,249. Generally, inflammation 
starts in endothelial cells in the brain as a consequence of seizures and mostly cytokines are 
upregulated by perivascular glia 223.   
Many studies found a correlation between seizures and inflammation. During SE, the exaggerated 
electric stimulation activated glial cells, causing an upregulation of proinflammatory mediators 
such as IL-1B, IL-6 and TNF-α 2,235,249. Generally, inflammatory mediators persist in low 
concentrations in a healthy neuronal environment, but these concentrations can easily increase 
when inflammation is triggered 236. In other study, some hallmarks of chronic inflammation like 
reactive gliosis and overconcentration of cytokines and chemokines have been found in the 
resected brain from epileptic patients, which emphasises the role of neuroinflammation in epilepsy 
232. A study conducted by Sakurai et al., reported evidence of neuronal death induced by seizures 
in cerebral tissue from dogs with epilepsy 250. This neuronal death was probably related to 
abnormal concentrations of inflammatory mediators such as TNF-α and IL-6 that were identified 
in these cerebral tissues 250.  
This finding suggests that seizures are responsible for the initiation of neuroinflammation that can 
persist and evolve to chronic inflammation.  The latter, in advanced stages, may be responsible 
for neuronal death and neurodegeneration 240,250. In a study by Bartels et al., levels of 
inflammatory cytokines in the CSF were significantly higher in dogs with IE than in healthy dogs, 
which emphasises the role of inflammation in the pathogenesis of IE 251. Similarly, high 
concentrations of TNF-α and IL-6 were found in the CSF of dogs with IE 252.





2. STUDY – EXPLORING THE IMPACT OF 




IE is known to be the most common neurological disease in dogs and humans 1,2,155. IE decreases 
the QoL of epileptic dogs when not treated, so adequate treatment with AEDs should be applied 
and formulated for each patient 210. Several AEDs are available for use in the treatment of IE but 
none of them provide cessation of epileptogenesis but instead only prevent seizures from 
occurring. Nonetheless, the relationship between epilepsy and inflammation has been discussed 
by many neuroscientists around the world and it is known that inflammation can trigger seizures 
and vice-versa 74,227,230. It is also well-known that hemogram can give valuable information 
regarding inflammatory processes in the organism, which makes it a useful tool in the diagnosis 
of several diseases.  
2.2. OBJECTIVE 
 
The focal objective of this study is to understand if there are relevant changes in the hemogram 
of epileptic dogs and whether these possible changes are related with inflammation. For this 
purpose, hemogram parameters of dogs who had experienced at least one seizure 24 hours 
before blood collection were evaluated and compared with non-peri-ictal values and with healthy 
animals, with the aim of detecting possible abnormalities in the hemogram related to inflammation.   
2.3. MATERIALS AND METHODS 
 
At the beginning of the study, three groups were hypothetically created. The control group or C1 
would be constituted by healthy dogs. The epileptic dogs included in this study will further be 
include on the epileptic group, divided into two different subgroups according to their chronological 
distribution. The epilepsy group after seizure would be listed as group E2 and the free-seizure 
epilepsy group would be listed as group E3. In order to be included in group E3, the selected 
epileptic dogs could not have had any seizure in the last three days prior to the blood collection. 
The interval of three days was selected based on half-life of neutrophils, which are closely related 
with inflammation. 




A total of 22 dogs were enrolled in this study between November 5th 2018 to April 5th 2019. From 
these 22 dogs, 16 were purebred (16/22) and six were cross-breed (6/22). Within purebred dogs, 
there were six Labrador Retrievers, two French Bulldogs, three Estrela Mountain dogs and one 
of the following breeds: Yorkshire Terrier, Chihuahua, Maltese, Pinscher and Boxer. From those 
22 dogs, 13 were male (59%) and nine were female (41%). The median age was 2.45 years 
(range 0.5-7.5 years). A total of 14 dogs (14/22) were included in the control group. From these 
14 dogs, six were male (6/14) and eight were female (8/14). Selected dogs to be included in the 
control group were dogs that had been admitted to the hospital to realise elective surgeries such 
as neutering. All these dogs were healthy with a normal physical examination and there were no 
abnormalities in both hemogram and serum chemistry.  
Eight of these 22 dogs (8/22) were included in the epilepsy group and seven of those dogs were 
male (7/8) and one was female (1/8). The eight dogs englobed in the epilepsy group had 
approximately a tier II level of confidence for the diagnosis of epilepsy. According to De Risio et 
al., a level of tier II confidence includes a history of two or more seizures, dogs aged between six 
months and six years, unremarkable interictal physical and neurologic examinations and 
undetectable abnormalities on hemogram, serum chemistry, urinalysis, fasting and post-prandial 
bile acids as well in the MRI 139. However, no measurement of fasting and post-prandial bile acids 
was performed since there were no detectable abnormalities on hemogram, serum chemistry and 
physical examination that could justify the necessity for such exams. The urinalysis was not also 
performed for the same reason. Another reason that justifies the absence of these exams was 
the financial constraints of owners, which could have had a negative impact on both diagnosis 
and treatment. All the eight dogs enrolled in the epileptic group have performed an abdominal 
ultrasonography. Out of the eight dogs, only two dogs had undergone an MRI and six had 
undergone a CT-scan because the latter is a cheaper imaging diagnostic exam. In the absence 
of abnormalities found in either a CT-scan or an MRI, analysis of CSF would not be performed.  
Some dogs have been excluded from this study since they were not suitable for the epileptic 
group due to a variety of reasons such as insufficient level of tier confidence, lack of collaboration 
from owners or the presumptive diagnosis was other than IE (e.g. distemper, intoxication and 
brain tumour) or concomitant diseases (e.g. chronic hepatitis).





All epileptic dogs included in this study were medicated with appropriate AEDs and all them 
started treatment with PB. In two of these eight dogs, it was necessary to add an additional AED, 
with one undergoing a combined therapy with KBr and another one with levetiracetam. All blood 
samples related to the subgroup E3 were collected during the treatment with AEDs. 
 
2.3.1. BLOOD COLLECTION AND HEMOGRAM 
PARAMETERS 
 
All blood samples for hemogram were collected by jugular venepuncture with a sterile, disposable 
23-gauge needle and 2mL syringe. Prior to blood collection, the puncture zone was shaved and 
disinfected with a pad impregnated with water-diluted 1% chlorhexidine. Alcohol was generally 
avoided since some animals are sensitive to it and alcohol may have led to an allergic reaction. 
Therefore, the blood sample collected was put onto a purple EDTA-tube containing 2% of K2 
Ethylenediaminetetraacetic Acid (EDTA). K2EDTA is an anticoagulant widely used and it is a 
good choice for blood analyses since it does not significantly change the blood parameters 253. 
Hemogram was performed straightway after blood collection to avoid alterations in the results, 
especially due to haemolysis. Hemogram was obtained from a BC-2800Vet auto haematology 
analyser, at the hospital laboratory (Table 7). This analyser is adapted for veterinary use and 
















Table  7: Reference blood parameters for dogs in a bc-2800 Vet Analyser. 
PARAMETERS VALUES 
White Blood Count (WBC) 6.0 - 17.0 
Lymphocytes 0.8 - 5.1 
Monocytes 0.0 - 1.8 
Granulocytes 4.0 - 12.6 
Lymphocytes % 12.0 - 30.0 
Monocytes % 2.0 - 9.0 
Granulocytes % 60.0 - 83.0 
Red Blood Count (RBC) 5.50 - 8.50 
Hemoglobin (HGB) 110 - 190 
Hematocrit (HCT) 39.0 - 56.0 
Mean Corpuscular Volume (MCV) 62.0 - 72.0 
Mean Corpuscular Hemoglobin 
(MCH) 
20.0 - 25.0 
Mean Corpuscular Hemoglobin 
Concentration (MCHC) 
300 - 380 
RDW (Red Distribution) 11.0 - 15.5 
PLT (Platelets) 117 - 460 




The questionnaire was based on the available literature about precipitating/risk factors associated 
with IE in dogs, as well as characterisation of seizures 8,25,39,47. The questionnaire comprised of 
17 questions of different categories: yes/no, multiple choice and short answers. The owners 
voluntarily answered the questionnaire and a face-to-face dialogue between the veterinarian, 
student and owner was established to obtain all the necessary information regarding each 
selected epileptic dog. Most of the owners have replied to the questionnaire while undergoing a 
check-up appointment, while others have gone to the hospital by request of their veterinarian, 
who offered a free appointment in exchange for their participation. Only seven from the eight 
owners of dogs with IE have completed the questionnaire. One owner left some answers 
regarding seizure’s characterisation blank because he did not witness any of the episodes. 
 
 




2.3.3. STATISTICAL ANALYSIS  
 
The dependent variables evaluated in this study were WBC, lymphocytes, monocytes, 
granulocytes, RBC, HGB, HCT, MCV, MCH, MCHC, RDW, PLT, MPV, PDW and PCT while the 
independent variables were the occurrence of a seizure or not. The SPSS software was used for 
the statistical analysis. Non-parametric tests have been chosen due to the small size of our 
samples. For independent samples, the Mann-Whitney test was used whereas the Wilcoxon 
Ranked test was used for dependent samples. Our level of confidence was settled to 0.05 and 




2.4.1. AGE, BREED, SEX AND WEIGHT  
 
In the epilepsy group, six of the eight dogs were under 20 kg (Figure 5). These results agree with 
their breed because most of the epileptic dogs were considered as small to medium breed 















Up to 10 kg 10 - 20 kg 20 - 30 kg Over 30 kg
Epilepsy 3 3 1 1










Figure 5: Characterization of the variable weight in both epileptic and 
control groups. 




From the 22 dogs englobed in this study, 13 dogs (13/22) were male while the other nine were 
female (9/22) (Figure 6). Within the epilepsy group, the incidence of male dogs was higher (7/8) 













From the 22 dogs enrolled in this study, 16 were pure breed (16/22). From these 16 pure-breed 
dogs, seven of them belonged to the epilepsy group (7/16). There is heterogeneity in breeds 
regarding epilepsy group, probably due to the small size of this population (Figure 7). The most 
common breed was Labrador Retriever (6/16) followed by the Estrela Mountain dog (3/16). 


























In what concerns to the age at first seizure, most of the epileptic dogs experienced their first 
seizure between one year and five years old (Figure 8). One of these dogs experienced its first 

















Up to 1 year 1 year - 3 years 3 years - 5 years 5 years or older
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Figure 7: Characterization of the variable breed in both epileptic and control groups. 
Figure 8: Age at the first seizure in the epileptic group. 






Regarding the signalment of the patient, none of the owners reported a family history of epilepsy. 
Similarly, none of the owners reported any trauma nor infectious/inflammatory/metabolic disease 
before the onset of seizures. One of the owners reported a reaction to the vaccination as possible 
trigger of seizures in his dog. Finally, none of the owners reported access to possible toxins or 
poisons but two of the eight epileptic dogs had access to the garden. 
Considering the duration of seizures, all owners reported that most of the epileptic episodes were 











Regarding the frequency of seizures, three of the owners reported a frequency of once per month 
while the other three reported seizuring events every six months. Only one owner reported a 
seizure per week (Figure 10). Two of the owners reported an increase in seizure’s frequency after 








1-2 minutes 2-3 minutes 3-5 minutes > 5 minutes
DURATION OF SEIZURES
Figure 9: Duration of seizures in the epileptic group. 














Four owners interviewed described a higher incidence of seizures while their dogs were 
sleeping/resting or straight after they awoke.  
Only two owners reported possible precipitating factors that possibly triggered seizures in their 
dogs. One of the owners stated that the onset of seizures was preceded by a change in the usual 
diet while another owner said that seizures occurred after moving to a new house and after using 
the vacuum cleaner.  
Loss of consciousness during the epileptic episode was reported by all owners in this study. The 
fact that all owners reported loss of consciousness together with a hard muscle tone, emphasises 
the hypothesis that all dogs enrolled in this study had suffered generalised seizures. Only two 
owners noted behaviour abnormalities following the epileptic episode. Both owners reported 
confusion and not recognising the owner/surrounding space as the main identifiable changes in 
the normal behaviour of their pets.  
When asked to write a brief description of the epileptic event, three of the owners described that 
their dogs were shaking during the episode, while the other four owners reported that their dogs 
were stiff. All owners have identified their dog’s muscle tone as rigid/hard. One of the owners 
observed pedalling/jerking movements during the episode and another one noticed that his dog 
had his tongue out of his mouth. One of the owners reported an improvement in the clinical 
manifestation of the seizures after starting the treatment. Initially, the seizures were classified as 
aggressive and autonomic signs were remarkedly visible whereas after initiating the treatment, 












Figure 11: Autonomic signs observed in the epileptic group. 
 
Figure 12: Autonomic signs observed in the epileptic group. 
 
Figure 13: RDW values distribution in the three groups.Figure 14: Autonomic 
signs observed in the epileptic group. 
Figure 15: Autonomic signs observed in the epileptic group. 
 




Figure 17: Autonomic signs observed in the epileptic group. 
 
Figure 18: Autonomic signs observed in the epileptic group. 
 
Figure 19: RDW values distribution in the three groups.Figure 20: Autonomic 
signs observed in the epileptic group. 
 
Figure 21: Autonomic signs observed in the epileptic group. 
Figure 10: Frequency of seizures in the epileptic group. 




Most of the owners noted some autonomic signs associated with the epileptic episode (Figure 
11). The most-reported autonomic sign was hypersalivation (6/7), followed by urination (2/7). 
Dilation of pupils, vomit and defecation was reported only once (1/7). Some owners reported more 





































2.4.3. HEMOGRAM PARAMETERS 
 
MCHC was significantly higher in the group C1 compared with the group E2 (p-value <0.05). On 
the other hand, RDW was significantly higher in the group E2 compared with the group C1 (p-
value < 0.005). The median of RDW was higher in the group E2 but an outliner was observed 
(Figure 12). The medians of WBC and granulocytes were higher in the group E2 whereas the 
median of lymphocytes was higher in the group C1 (Table 8).  
 
Table  8: Comparison of hemogram parameters between the group control and epilepsy group 
after seizure. 
Mann-Whitney test C1 (n=14) E2 (n=8) p-value 
Median ± SD 
WBC 11.2 (8-15.9) 12.9 (5.6 – 16.5) 0.707 
LYMP 2.05 (1-3.6) 1.95 (0.8 – 2.6) 0.338 
MON 0.5 (0.3 – 0.6) 0.4 (0.2-0.6) 0.550 
GRAN 8.6 (4.5 – 12.9) 10 (4.6 – 13.8) 0.561 
RBC 7.6 (5.63-10) 7.805 (6.96-8.79) 0.393 
HGB 180 (145-198) 182 (144-209) 0.758 
HCT 56.85 (44.9 – 61.6) 59.3 (48.1-66.1) 0.161 
MCV 73.75 (71.3-80.2) 75.3 (69.2-78.4) 0.584 
MCH 23.85 (21.5-25.8) 23.35 (20.6-24.5) 0.193 
MCHC 317.5 (296-342) 308 (294-316) 0.018 
RDW 14.05 (9.7-15.3) 15.35 (10.5-15.9) 0.015 
PLT 403.5 (125-581) 361.5 (269-536) 0.473 
MPV 8.55 (7.8-9.8) 8.85 (7.3-10.7) 0.706 
PDW 16.3 (16-17) 16.4 (16.1-17.3) 0.679 
















There were no significant statistical differences between parameters from the group C1 and the 
group E3. The median of lymphocytes was slightly higher in the group E3 compared with the 
group C1. The HBG and HCT medians were also higher in the group E3 whereas the medians of 
red cells indices like MCV, MCH and MCHC were higher in the group C1 (Table 9). 
 
Table  9: Comparison of hemogram parameters between the control group and free-seizure 
epilepsy group. 
Mann-Whitney test C1 (n=14) E3 (n=8) p-value 
Median ± SD 
WBC 11.2 (8-15.9) 11.4 (8.2-15.6) 0.972 
LYMP 2.05 (1-3.6) 3 (1.3 – 4) 0.150 
MON 0.5 (0.3 – 0.6) 0.5 (0.3-0.6) 0.887 
GRAN 8.6 (4.5 – 12.9) 7.3 (6.5 – 12.2) 0.339 
RBC 7.6 (5.63-10) 8.075 (6.33 – 8.87) 0.133 
HGB 180 (145-198) 194 (141-208) 0.132 
HCT 56.85 (44.9 – 61.6) 58.15 (45.3-66.1) 0.494 
MCV 73.75 (71.3-80.2) 72.4 (69.4-79.7) 0.231 
MCH 23.85 (21.5-25.8) 23.7 (22.2-24.8) 0.452 
MCHC 317.5 (296-342) 314.5 (311-342) 0.891 
RDW 14.05 (9.7-15.3) 14.65 (13.2-15.3) 0.192 
PLT 403.5 (125-581) 423.5 (292-548) 0.538 
MPV 8.55 (7.8-9.8) 9 (8.6-9.9) 0.055 
PDW 16.3 (16-17) 16.55 (16.1-17) 0.192 
PCT 0.3475 (0.102-0.48) 0.4 (0.26-0.53) 0.356 
 
Figure 12: RDW absolute values distribution in the three groups. 




The lymphocytes were significantly higher in the E3 group compared with the E2 group (p-value 
< 0.05). The median of lymphocytes was smaller in the group E2 and the dispersion of values is 
higher in the E3 group (Figure 13). The medians of WBC and granulocytes from the E2 group 
after seizure were higher when compared with the E3 group. The median of RBC and HGB were 
significantly higher in the E3 group but the median of HCT was higher in the E2 group (Table 10). 
 
Table  10: Comparison of hemogram parameters between epilepsy group after seizure and 
free-seizure epilepsy group. 
Wilcoxon Ranked Test E2 (n=8) E3 (n=8) p-value 
Median ± SD 
WBC 12.9 (5.6 – 16.5) 11.4 (8.2 – 15.6) 0.484 
LYMP 1.95 (0.8 – 2.6) 3 (1.3 – 4) 0.021 
MON 0.4 (0.2 – 0.6) 0.5 (0.3 – 0.6) 0.340 
GRAN 10 (4.6 – 13.8) 7.3 (6.5 – 12.2) 0.483 
RBC 7.805 (6.96 – 8.79) 8.075 (6.33 – 8.87) 0.889 
HGB 182 (144 – 209) 194 (141 – 208) 0.207 
HCT 59.3 (48.1 – 66.1) 58.15 (45.3 – 66.1) 0.484 
MCV 75.3 (69.2 – 78.4) 72.4 (69.4–79.7) 0.674 
MCH 23.35 (20.6 – 24.5) 23.7 (22.2 – 24.8) 0.123 
MCHC 308 (294 – 316) 314.5 (311 – 342) 0.630 
RDW 15.35 (10.5 – 15.9) 14.65 (13.2 – 15.3) 0.262 
PLT 361.5 (269 – 536) 423.5 (292 – 548) 0.237 
MPV 8.85 (7.3 – 10.7) 9 (8.6 – 9.9) 0.233 
PDW 16.4 (16.1 – 17.3) 16.55 (16.1 – 17) 0.725 




Figure 13: Lymphocytes absolute values distribution in the three groups. 






The results obtained in this study demonstrate few statistically significant differences between 
groups, yet these results are interesting. In addition, the findings that are not deemed to be 
statistically significant are still worth considering. 
In the study, most of the dogs included in the epilepsy group were small breed dogs. This differs 
from what has been discussed in a study by Podell et al. that found a higher prevalence of IE in 
medium to large breeds, mostly over 15 kg 16. However, these results may be related to the 
popularity of small to medium breeds in Portugal, especially French Bulldogs, Yorkshire Terriers 
and Chihuahuas. 
Different breeds were included in the epilepsy group but despite this heterogeneity, most of the 
breeds observed in the epilepsy group have been previously described as predisposed to IE. 
Some of these breeds include the Labrador Retriever 18,23,26, and the Chihuahua 15. Other breeds 
like Maltese dog, Yorkshire Terrier and French Bulldog are not described as predisposed to IE, 
but are associated with other diseases that may mimic seizures like hydrocephalus 254. 
Additionally, pinscher dogs have been previously associated with cataplexy 254. The Estrela 
Mountain dog has only been associated to a higher predisposition for hip dysplasia 255 and there 
is a lack of information regarding other diseases in this breed. Given it is a common breed in 
Portugal, this increases the likelihood of finding this breed in a clinical setting. A study conducted 
by Kearsley-Fleet et al., investigated the possible role of coat-colour type and coat length as risk 
factors for IE 20. A statistically significant association was found between long-coat/multicolour-
coat and IE. Whether these results suffer from a bias effect is not clear. No other studies have 
analysed the relationship between coat’s characteristics and IE.  
Regarding gender, almost all dogs included in the epilepsy group were male. Three of these eight 
dogs were neutered and all the neutered dogs were male. These results are in accordance with 
other studies, where the proportion of male dogs with IE was higher 15,23,24. Notwithstanding, the 
relationship between neutering and IE remains unclear. One study reported that neutered female 
dogs were less likely to have seizures than non-neutered female dogs 23,42, while another study 
reported that neutered male dogs with IE had a shorter survival time compared with non-neutered 
male dogs 256. Nonetheless, the relationship between gender and IE is still unknown and many 
believe that sex hormones like testosterone may be involved. The higher incidence of females in 
the control group may be explained by the fact that most of owners wanted to neuter their bitches, 
thereby avoiding undesirable pregnancies.  
Most of the dogs included in the epilepsy group experienced their first seizure within their first to 
fifth year of age. This finding is in agreement with other studies, which reported the likelihood of 
diagnosing IE in dogs aged between six months to six years old 33,34. The fact that most dogs 




diagnosed with IE are young makes the diagnosis of StE less likely. Also, all dogs included in the 
epilepsy group underwent an MRI or a CT-scan and none structural anomalies in the brain were 
detected. According to Smith et al., the prevalence of clinically relevant abnormalities detected 
from an MRI is relatively low in animals younger than six years old 34.  
None of the owners reported a family history of epilepsy. However, this does not exclude the 
possibility of genetic factors associated with the epileptic dogs since owners may not have access 
or be aware of that information. One of the owners reported a reaction to the vaccination who 
may have triggered seizures in his dog, however there are no studies in veterinary literature 
reporting such a situation. Nonetheless, seizures induced by vaccination have been reported in 
humans, which might be explained by physiological stress induced by the immunological 
response 257. Therefore, in this case, vaccination might be seen as a precipitating factor.  
All owners reported that most of epileptic events were not longer than five minutes and this finding 
is comparable to what has already been reported by Berendt and Gram that most of the seizures 
last up to 2 minutes 117. In other study, Heynold et al.  reported a mean duration of three minutes 
and a half 44. 
Three owners reported seizure frequency of once per month while the other three owners reported 
a seizure every six months. This is similar to what was been found in a study by Heynold et al., 
where the reported average frequency was one seizure every 65 days 44 and in another study by 
Jaggy and Bernardini, the frequency of seizures ranged between two seizures every day to one 
every six months. However, most of the dogs had less than one seizure per month 37. Only one 
owner reported a seizure per week and as previously said, this was related with the fact that his 
dog was recently diagnosed. 
Two owners reported an increase of frequency after the first episode. An increase in frequency 
after the first seizure has been reported in some studies, but mostly related to either treatment 
failure 258 or absence of treatment. A reasonable explanation may be the fact that sometimes the 
time between diagnosis and initiation of treatment is longer, possibly due to economic restraints 
that prevent the realisation of more specific exams such as a CT-scan or an MRI. 
Four owners described a higher incidence of seizures during sleeping/resting or straight after 
awaking. This agrees with what has already been described by Pákozdy et al., who said that a 
diagnosis of IE was likely when dogs experienced seizures during their period of rest 35. Also, 
Podell et al., said that, in a non-referral-based population, most of the seizures occurred between 
midnight and 8 am, which includes some moments of resting and sleep 16. 
Only two owners identified possible precipitating factors that could have possibly triggered 
seizures in their dogs. These precipitating factors are not completely understood but have already 
been reported in some studies and are mainly associated with stress 39. Stress changes the 
normal homeostasis, leading to a response of the organism to this imbalance 259. Any situation 




that leads to physiological stress may have the potential to trigger seizures. Precipitating factors 
may vary between dogs, depending upon their temperament, age, sex, among others. In a study 
by Forsgard et al., owners reported stress as being the most common precipitating factors that 
were observable 39. In the same study, changes in the normal daily routine were another common 
precipitating factor identified by owners, which agrees with what was reported by one of the 
owners in this study. 
All owners reported loss of consciousness during the epileptic episode. In a study by Heynold et 
al., 41 of the 49 dogs enrolled lost their consciousness during the epileptic episode 44. In another 
study by Jaggy and Bernardini, 75% of the dogs with generalised seizures lost their 
consciousness 37. Loss of consciousness is generally associated with generalised seizures and, 
in some focal seizures, consciousness may be unimpaired 1. Whether consciousness is impaired 
or not, is difficult to assess since dogs do not express their feelings about their experiences. Also, 
owners may misunderstand those signs and think that their dogs are conscious when they are 
not and vice-versa. For this reason, the IVETF downplay the importance of evaluating 
consciousness in veterinary medicine. In the questionnaire, all the owners described their dog’s 
muscle tone as rigid/hard during the epileptic episode. During generalised seizures, which are 
known to be the most common presentation in dogs, the tonic phase is characterised by a 
generalised increase in muscular tone as a consequence of multiple electrical discharges during 
the episode 1. 
The most common autonomic sign identified was hypersalivation, followed by urination. This 
agrees with what was already been found in other studies, which identified these autonomic signs 
as common 1,9,139. 
From the eight dogs included in the epilepsy group, six of them were on monotherapy with PB 
and two of them on a combined therapy with PB, one with KBr and another one with levetiracetam. 
Blood samples from group E3 were collected after initiating treatment so blood parameters could 
be affected by AEDs. Some studies have associated PB to megaloblastic anaemia, which is 
mainly observed in cases of deficiency in folic acid or cobalamin vitamins 260,261. Folic acid and 
cobalamin are vital to erythropoiesis because of their role in the proliferation and differentiation of 
erythroblasts 262. PB induces the cytochrome P450 enzyme which has the potential to increase 
the metabolism of folic acid, leading to a decrease of its serum levels 263. Without acid folic and 
cobalamin, the erythropoiesis is compromised leading to a megaloblastic anaemia. According to 
Moore, megaloblastic anaemia is defined by a pancytopenia in association with macrocytic 
erythrocytes that are not fully differentiated 263. 
None of the dogs included in this study presented values of blood parameters that could suggest 
an underlying anaemia. However, RDW was significantly higher in the group E2 when compared 
with the control group. RDW refers to the red cell width distribution and represents the size 
heterogeneity of RBC. RDW may increase in situations that require a high demand of RBC 




because reticulocytes, that are bigger than mature erythrocytes, are released into the 
bloodstream.  On the other hand, RDW may be decreased in situations where production and 
maturation of RBC are impaired. RDW may also be affected by inflammation because an increase 
in the inflammatory cytokines contributes to a non-regenerative anaemia by inhibiting the 
production of erythropoietin and its receptors as well as affecting the normal iron metabolism 
264,265. It would be expected to see a decreased RDW in the group E2, induced by a hypothetical 
chronic inflammation but these results are not in agreement with that hypothesis.  
RDW has also been associated with hypoxia and this blood parameter has been suggested as a 
possible biomarker for hypoxia-inducing diseases 266–268. During seizures the uncontrolled 
contraction of multiple groups of muscles such as the respiratory muscles may lead to airway 
obstruction and breathing issues, consequently initiating a status of hypoxemia 269. The underlying 
hypoxemia during seizures may increase the risk of cerebral hypoxia, aggravating the symptoms 
if not treated. A study conducted by James et al., described a decrease of 14.5% of arterial oxygen 
saturation in humans during seizures, which easily returned to normal values after the epileptic 
event. A status of hypoxemia increases the RDW by leading to a widespread release of 
erythrocytes into the bloodstream with the aim to increase the inflow of the circulating oxygen. In 
this study, none of the dogs demonstrated decreased levels of the number of erythrocytes, HCT 
or HGB, which rules out the possibility of anaemia that could increase the RDW by inducing 
regenerative response. Therefore, the RDW elevation in the E2 group may be due to the brief 
status of hypoxia caused by seizures or a result of inflammation-inducing seizures. 
MCHC refers to the mean corpuscular HGB concentration and it was significantly lower in the E2 
group when compared with the control group (p-value <0.05). MCHC is related with HCT and 
HGB and this relationship is expressed in the formula 𝑀𝐶𝐻𝐶 =
𝐻𝐺𝐵
𝐻𝐶𝑇
. HCT and HGB medians in 
the E2 group were slightly higher compared with the control group, which does not explain why 
MCHC is lower in the E2 group. Nonetheless, RDW was significantly higher in the E2 group, which 
may explain a lower MCHC if in the presence of a significant increase of erythrocytes’ size. If 
reticulocytes are mainly released into the bloodstream during the seizures, it is expected to see 
a diminution of MCHC as consequence of an increase of erythrocytes’ size, which makes the 
MCHC appear lower. The MCV refers to the mean corpuscular volume and the median of this 
blood parameter was slightly increased in the E2 group when compared with the control group, 
which empathises the hypothesis of a lower MCHC as consequence of larger, younger 
erythrocytes in circulation.  
Other haematologic abnormalities that have been associated to PB administration included 
leukopenia and thrombocytopenia 180,270,271, which have not been observed in any of the dogs 
undergoing treatment in this work. The mechanism responsible for leukopenia and 
thrombocytopenia induced by PB remains unclear. A study reported that leukopenia could be 




induced by destruction of mature granulocytes 272 while other study suggested that such 
anomalies could be explained by bone marrow necrosis provoked by PB 273.  
On the other hand, monotherapy with KBr has not been associated with haematological 
abnormalities. Levetiracetam is a common choice as an add-on drug but some studies have 
reported haematological abnormalities associated with this drug when used in human medicine. 
In one study, monotherapy with levetiracetam was associated with thrombocytopenia 274, while in 
a case-report study it has been associated with pancytopenia 275. Nevertheless, there is minimal 
evidence regarding the haematological abnormalities induced by levetiracetam in dogs.  
Lymphocytes were significantly higher in the E3 group compared with the E2 group (p-value < 
0.05). Lymphocytes are cells of major importance for the acquired immune response. In acute 
inflammation, the innate immune system is the first pathway activated in response to a noxious 
stimulus against the organism. Nonetheless, acquired immunity is mainly associated with a late 
and specialised response, which may be mainly involved in chronic processes. It is hypothesized 
that, in dogs suffering recurrent seizures, the acquired immune response is activated, leading to 
an increase of free-circulating lymphocytes in the bloodstream and chronic inflammation. 
Consequently, discrete lymphocytosis can be observed on the hemogram. The fact that 
lymphocytes were significantly higher in group E3 compared with group E2 supports the 
hypothesis that these dogs may experience underlying chronic inflammation, related with 
recurrent seizures. Decreased lymphocytes in group E2 when compared with group E3 is also 
compatible with stress leukogram changes due to recent seizures. 
Even though there was no statistically significant relationship observed in WBC between groups, 
the median of WBC was slightly higher in group E2 compared with the group C1 and group E3. It 
is not clear which mechanism leads to an increase of WBC following seizures, however, one study 
suggested that WBC increases as a result of intense muscular activity and subsequently the 
release of epinephrine leads to demargination of leukocytes 219. Stress and inflammation could 
also explain this increased in leukocyte number, regardless of the mechanism.  
The neutrophils/lymphocytes ratio (NLR) could not be measured since the blood analyser used 
in this study did not provide the absolute value of circulating neutrophils, only granulocytes and 
eosinophils. NLR has shown to be a biomarker for some inflammatory diseases in humans 276,277 
and could have been useful when assessing possible underlying inflammation in the epileptic 
dogs. The median of granulocytes was higher in group E2 compared with the control group and 
group E3. Since neutrophils are the most abundant granulocytes 278, it is hypothesised that the 
median value of granulocytes may be mainly changed by the absolute number of circulating 
neutrophils, leading to speculation of a higher NLR in the group E2 compared with the other 
groups, possibly reflecting inflammation. However, blood smears from these dogs were not 
analysed so it is not possible to conclude whether a higher absolute value of granulocytes was 
due to a major concentration of neutrophils, eosinophils or basophils. Nevertheless, it is not 




common to observe basophilia on hemogram and percentage of eosinophils was not elevated in 
any of these dogs. As stated by Rebar, basophilia is rarely seen on the hemogram and when 
present, it is observed together with eosinophilia 278. 
Stress leukogram is normally seen after stress-related situations that induce inflammation and is 
characterised by lymphopenia, mild mature neutrophilia, eosinopenia and mild monocytosis 214. 
In dogs, it is common to see a marked neutrophilia and mild polycythaemia in the stress 
leukogram 214. The granulocytes were higher in group E2 compared with group E3, which supports 
the theory of stress leukogram in dogs that suffered seizures. The median of HCT was elevated 
in group E2 which may suggest mild polycythaemia that may be associated with stress leukogram.  
Because epilepsy has been linked to inflammation in several studies in humans 74,100,227–229, it is 
thought that non-steroidal anti-inflammatory drugs (NSAIDs) may have an important role in 
stopping epileptogenesis, especially in cases where the conventional AEDs do not work 249. 
However, it is not yet known how NSAIDs should actuate on inflammatory pathways to avoid 
triggering seizures 279. 
This study was performed during a 5-months externship in a clinical setting at a single veterinary 
hospital in Portugal, thereby limiting the number of animals included in this study. Therefore, the 
information and data from these dogs was collected during normal daily-basis clinical routine. All 
blood samples were collected during medical appointments and all owners were aware of the 
procedures.  
The fact that this study was performed during this externship limited the sample of our population, 
as well as the diagnostic exams performed due to financial restraints of the owners. During the 
normal daily clinical routine, some diagnostic exams are preferred over others because some of 
these exams may be avoidable if no other abnormalities are found. For instance, if no 
abnormalities are found on serum chemistry regarding the hepatic functionality, fasting and 
postprandial bile acids may not be performed since the likelihood of finding abnormalities on this 
exam will be lower. The same may be applied for urinalysis if no alterations are found regarding 
creatinine and urea serum concentrations. The CSF analysis is another diagnostic exam included 
in the tier II confidence level that is normally not performed if no abnormalities are found on either 
a CT-scan or an MRI. It is often the case in Portugal, that most owners have financial restraints 
so most of the times, our diagnosis must be directed to the most important exams that should be 
performed with consideration given to the potential cost to owners. Some owners may have the 
willingness to have a definitive diagnosis and treat their pets but some of them may give up on 
some decisions due to financial constraints. Therefore, it is of great importance to initially select 
the most important diagnostic exams that are likely to reveal the most amount of information 
regarding the diagnosis. The fact that not all the dogs underwent the same diagnosis protocol 
may have affected the results of this study. The budget was also limited since this study was not 
financed by any institution but the hemograms performed were offered by the veterinary hospital. 




Moreover, not all the dogs underwent the same treatment of epilepsy, which could have also 
affected the results.  
At the beginning of this study, it was thought to include C-reactive protein (CRP) as a possible 
biomarker for inflammation. In humans, CRP has been identified as a high-sensitivity biomarker 
for inflammation. CRP is one of the main acute phase proteins (APP) recognised and it is widely 
used as biochemical tests for supporting diagnosis of several diseases such as leishmaniosis, 
leptospirosis or babesiosis in dogs 280,281. Also, diagnosis of other non-infectious inflammatory 
diseases may be supported by serum concentrations of CRP including arthritis and canine 
inflammatory bowel disease. 280 
However, measurement of serum CRP is an expensive and low-specificity biochemical test 281  
since it may be increased in the presence of several inflammatory conditions. Given these 
enumerated reasons, from which the cost was the foremost, it was decided to not include CRP 
measurement in this study, despite its potential benefits in identifying inflammation. 
Assessing an empirical albumin/globulin ratio could have been another interesting analysis that 
could have been included in this study. A decreased albumin/globulin ratio could reflect 
inflammation due to a markedly concentration of globulins over albumin 282, which may also be 
decreased in inflammatory processes. However, this could not be assessed because not all the 
veterinarians that were following these epileptic dogs have analyzed both serum total protein and 
albumin while undergoing their diagnosis.  
2.6. CONCLUSION 
 
The existence of a relationship between epilepsy and inflammation is becoming more widely 
recognised. The fact that inflammation may trigger epilepsy and vice-versa makes the 
inflammatory mediators possible biomarkers for this disease. Also, a better understanding of 
inflammatory pathways in epilepsy could be of a great value to produce novel AEDs. Because 
epilepsy has been linked to inflammation in several studies in humans 74,100,227–229, it is thought 
that NSAIDs may have an important role in stopping epileptogenesis, especially in cases where 
the conventional AEDs do not work 249. However, it is not yet known how NSAIDs should actuate 
on inflammatory pathways to avoid triggering seizures 279. 
Currently there is a lack of effective drugs with little side effects and higher effectiveness praise 
the necessity to seek novel drugs that could be used in the treatment of IE. The new consensus 
regarding IE in veterinary medicine brought a better understanding between veterinarians 
regarding the classification and management of this disease, from the diagnosis to the prognosis. 
As epilepsy is a syndrome that is often misunderstood, especially regarding its pathophysiology, 
makes it harder to manage and treat such a disease.  In addition, the fact that the costs of 




diagnosing and treating IE are expensive due to the lack of government funding makes it even 
more difficult to ensure that this correctly managed.   
Nowadays, most clinics and hospitals have blood analysers available for immediate use alongside 
large amount of data on hemogram parameters. However, it is not possible to directly relate 
hemogram parameters with IE unless in ruling-out other diseases. For this reason, a hemogram 
cannot be used alone to diagnose IE and since this is a complex disease, it is likely that the 
hemogram will never be considered as a gold standard test. Nevertheless, the fact that 
inflammation is suggested through hemogram parameters on these epileptic dogs highlights the 
relationship between epilepsy and inflammation. This relationship is interesting and may be 
helpful for the development of new novel drugs that act directly on specific inflammatory 
pathways.  
Idiopathic epilepsy may not be defined as an inflammatory disease but its relationship with 
inflammation is becoming widely accepted, so assessing some inflammation biomarkers could be 
important in understanding a possible relationship between epilepsy and inflammation. Currently, 
some of the APPs known include CRP, serum amyloid A, alpha 1-acid glycoprotein and 
haptoglobin, which have a satisfactory diagnostic sensitivity for inflammation in dogs 280. Thus, 
these potential biomarkers could be studied to understand whether they are markedly expressed 
following epileptic events. Inflammatory mediators such as ILs, chemokines and TNF-α could be 
of great value to understand their potential effects on the neuronal environment and its 
constituents. Measuring these inflammatory mediators could clarify whether they contribute for 
reactive gliosis and neuronal death, potentially aggravating the seizures. Glutamate could be also 
a potential target to assess its effects when overconcentrated in the brain tissue of epileptic dogs. 
Finally, it is widely accepted that idiopathic epilepsy is strictly related with genetic mutations and 
some genes have been identified in humans and dogs. In Lagotto Romagnolo dogs, a mutation 
on the LGI2 gene, encoding a protein strictly related with synaptic transmission, has been 
identified as a genetic cause for epilepsy 31,283. Similarly, a type of epilepsy in humans was found 
to be induced by a mutation on the LGI1 gene 283. Even though the gene involved is different from 
the one found in dogs, the proteins encoded belong to the same family, which highlights the 
relationship between these proteins and epilepsy. Mutations on these genes that lead to 
dysfunctions of these specific proteins are of a great interest as well.  
This study suggested a relationship between epilepsy and changes in hemogram parameters, 
possibly triggered by underlying inflammation following seizures. However, it is not possible to 
guarantee the existence of a relationship between epilepsy and inflammation in this study since 
our sample was small and data limited to haematology. The fact that this is a preliminary and 
exploratory study encourages more studies on this subject, especially because some statistically 
significant results were obtained despite a small sample.  




More studies on this topic should be encouraged in the future, enlarging the sample and 
assessing inflammation biomarkers, so that management of epilepsy can be easier for both 
veterinarians and owners and more importantly to allow for an improvement in the QoL of epileptic 
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Sex  Breed Age at the first 
onset 
Weight Group 
1 Male Labrador Retriever 4 years 36.5 kg Control 
2 Female Cross-Breed 1-year e 5 
months 
36 kg Control 
3 Male Labrador Retriever 6 years 38.6 kg Control 
4 Female French Bulldog 2 years 12.45 kg Control 
5 Male Estrela Mountain 
Dog 
7 months 42.4 kg Control 
6 Male Cross-Breed 2 years 6.7 kg Control 
7 Male Cross-Breed 1-year and half 20.9 kg Control 
8 Female Cross-Breed 1-year 19.5 kg Control 
9 Female Estrela Mountain 
Dog 
1 year and half 34.6 kg Control 
10 Female Labrador Retriever 5 months 13.2 kg Control 
11 Female Boxer 2 years 25.3 kg Control 
12 Female Labrador Retriever 7 months 21,3 kg Control 
13 Male Labrador Retriever 2 years 22 kg Control 
14 Female Cross-Breed 1-year and 6 
months 
16 kg Control 
15 Male 
neutered 
Pinscher 4 years and 5 
months 
3.80 kg Epilepsy 
16 Male 
neutered 
Maltese Dog 5 years and 5 
months 
12.50 kg Epilepsy 
17 Female non- 
neutered 
Yorkshire Terrier 1-year and 4 
months 
1.95 kg Epilepsy 




10 months 26.5 kg Epilepsy 
19 Male 
neutered 
Labrador Retriever 5 years and 9 
months 
34.40 kg Epilepsy 
20 Male non- 
neutered 
French Bulldog 3 years 17.30 kg Epilepsy 
21 Male non-
neutered 
Cross-Breed 3 years and 5 
months 
11.00 kg Epilepsy 
22 Male non-
neutered 
Chihuahua 2 years 2.65 kg Epilepsy 
23 Male 
neutered 









3 years and 1 
month 
3.25 kg Excluded – 
Insufficient 







Labrador Retriever 4 years 32 kg Excluded – 
















German Shepard 1-year and 7 
months 





Boxer 9 years 23 kg Excluded – 
Possible brain 
tumour 
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